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STATISTICAL INFERENCES FOR TWO-STAGE TREATMENT REGIMES
FOR TIME-TO-EVENT AND LONGITUDINAL DATA
Sachiko Miyahara, PhD
University of Pittsburgh, 2009
Adaptive treatment regime is a set of rules that governs the assignment of time-varying
treatment based on observed covariates and intermediate response. Treatment choices are
made sequentially as patients make transition from one health state to another. Specifically,
in two stage randomization designs, patients are randomized to one of the initial treatments,
and at the end of the first stage, they are randomized to one of the second stage treatments
depending on the outcome of the initial treatment. The goal is to find the best treatment
regime which produces the best terminal outcome. For time-to-event data, the best outcome
is the longest survival time, and for longitudinal data, the best outcome is greatest reduction
(or increase) in some scores such as reduction 24-item Hamilton Rating Scale of Depression
(HRSD24) score. For time-to-event data, we propose a weighted Kaplan-Meier estimator
based on the method of inverse-probability weighting and compare its properties to that
of the standard Kaplan-Meier estimator, and two other existing methods such as marginal
mean model based estimator and weighted risk set estimator. For longitudinal data, outcome
such as HRSD24 scores are collected repeatedly to monitor the progress of the subject. We
propose three methods incorporating inverse probability weighting, mixed models, multiple
imputations, and pattern mixture models to assess the effect of treatment regimes on the
longitudinal HRSD24 scores. Methods are compared through simulation studies with an ap-
plication to a depression study. Assessing the effect of treatment regimes on longitudinally
observed outcome data is important in Public Health since clinicians will be able to identify
effective treatment regimes for treating chronic diseases. Proposed statistical methods pro-
iv
vide useful tools for unbiased estimation of the effects of treatment regimes from sequentially
randomized designs. Availability of these methods will help advance the research in AIDS,
cancer, depression, hepatitis and other disease areas.
Keywords: Dynamic Treatment Regimes, Adaptive Treatment Strategies, Weighted Kaplan-
Meier Estimator, Inverse Weighting, Mixed Models, Missing Data, Repeated Measure-
ment.
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1.0 INTRODUCTION
1.1 ADAPTIVE TREATMENT REGIME
Adaptive treatment regime, also known as dynamic treatment regime, is a set of rules that
governs the assignment of time-varying treatment based on observed covariates and inter-
mediate response. Treatment choices are made sequentially as patients make transition from
one health state to another. The goal is to find the best treatment regime which produces the
best terminal outcome, where the best outcome can be the longest survival time or greatest
reduction in some scores such as Hamilton Rating Scale of Depression (HRSD24) score. As
such, this idea of adaptive treatment regimes appeals the clinicians treating complex diseases
such as cancer, AIDS, and depression.
Sequentially randomized trials are often used to investigate the effect of adaptive treat-
ment regimes. For example, suppose there are two treatment options A1 and A2 at the first
stage and two treatment options for both responders (B1 and B2) and non-responders (B
′
1
and B′2) at the second stage. In sequentially randomized designs, patients are randomized
to A1 or A2 followed by another randomization at the second stage, to B1 or B2 if the
patient is a responder or to B′1 or B
′
2 if the patient is a non-responder. With this design,
one can investigate a total of eight treatment regimes, namely, AjBkB
′
l, j, k, l = 1, 2 where
AjBkB
′
l stands for “Treat with Aj followed by Bk if respond, by B
′
l if otherwise.” Number
of treatment options in second stage may vary between responders and non-responders. For
example, in a leukemia trial described in Stone et al. [1], patients not responding to the
initial stage treatment were not treated any further (see Chapter 3).
Statistical inference on treatment regimes using a summary outcome measure has been
well-studied in literature. For example, estimation of a mean response based on observational
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longitudinal data are proposed in Murphy, Van Der Laan and Robins [2] and Murphy [3].
Methods for survival outcomes were considered in Lunceford et al. [4], Wahed and Tsiatis
[5, 6], Guo and Tsiatis [7], Hernan et al. [8], Lokhnygina and Helterbrand [9]. Thall et
al. [10] adapts a Bayesian approach to model the time to failure and compare two-stage
adaptive treatment regimes.
1.2 GOALS AND ORGANIZATION
In this thesis, we worked on two different areas of estimations within the framework of
adaptive treatment regimes in two-stage designs. One area is the estimation of survival
distributions. The goal in this case is to estimate the survival distribution of the patient
population following a specific regime based on the data collected through a two-stage ran-
domization design. The other area is the estimation of treatment effect when the data are
collected longitudinally. In this case, the goal is to assess the treatment effect over time for
each treatment regime.
In Chapter 1, we introduced the idea of adaptive treatment regimes, and in Chapter 2,
survival analysis, mixed models, and missing data methods are reviewed as they will be our
common tools for developing methods for adaptive treatment regimes. In Chapter 3, we
propose a weighted Kaplan Meier estimator for two-stage treatment regimes. In order to
accommodate the loss due to the second randomization, a standard Kaplan Meier estimator
was modified using the inverse-probability weighting method. Through simulation studies,
the proposed methods were examined in large sample properties, and we compared the result
with the ones from two existing estimators. In Chapter 4, we propose two methods to assess
the effect of treatment regimes on longitudinal outcome data in two-stage designs. First
method is referred to as two-step method since the overall treatment effects for all regimes
are estimated in two steps. At the first step, the effect for each treatment sequence is
estimated using mixed model techniques, and at the second step, the effects of treatment
regimes are estimated by taking their weighted averages. The second method uses a multiple
imputation approach to reconstruct observations for subjects who did not follow the regime
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of interest. This method involves one extra step of multiple imputations and hence will be
referred to as three-step method. The proposed methods were examined through simulation
studies. In Chapter 5 we propose a method adapting pattern mixture models to assess the
effects of treatment regimes when the data are not missing at random and have a monotone
missing pattern. First, the data were stratified by the missing data pattern within each group
of observed treatment sequence. Then the parameter of interest was estimated within each
strata, and the treatment sequence effects were estimated by taking the weighted averages.
Finally the overall treatment regime effects were estimated by combining the estimated
treatment sequence effects with the empirical missing data response rate. The simulation
studies were conducted to examine the performance of the proposed method.
3
2.0 METHODOLOGY REVIEWS
Methods used for the following chapters are reviewed in this chapter. In sub-section 2.1,
we present an overview of standard Kaplan-Meier and Nelson-Aalen methods for estimating
survival distribution. An overview of mixed models is included in sub-section 2.2. Finally, in
sub-section 2.3, different types of missing data, multiple imputation methods, and pattern
mixture models are explained.
2.1 KAPLAN-MEIER AND NELSON-AALEN ESTIMATORS
Methods for analyses of right censored data includes Kaplan-Meier, Nelson-Aalen, and Cox
proportional hazard models. The Kaplan Meier estimator [11], also known as Product Limit
estimator, is one of the most common method for estimating survival distribution of right
censored data. Let S(t) be the survival rate at time t, the Kaplan-Meier estimator is ex-
pressed as follows
Ŝ(t) =
 1, t < t1Πtm≤t(1− dmYm ), t ≥ t1
where dm =
∑n
i=1 ∆iI(Vi = tm), Ym =
∑n
i=1I(Vi ≥ tm), Vi is the observed time to event
(i.e. a minimum of time to event Ti and a censored time Ci), and tm,m = 1, 2, . . . , are the
distinct ordered failure times. The variance of Kaplan-Meier estimator can be estimated by
Greenwood formula [12] as follows
V̂
[
Ŝ(t)
]
= Sˆ(t)2
∑
tm≤t
dm
Ym(Ym − dm) .
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Another simple and common method for estimating survival distribution is the Nelson-Aalen
estimator [13], the estimated survival distribution can be expressed as follows
Ŝ(t) = Exp[−Ĥ(t)]
where the cumulative hazard is estimated by
Ĥ(t) =
 0, t < t1Πtm≤t( dmYm ), t ≥ t1
The estimated variance of the Nelson-Aalen estimator is as follows
σ2H(t) = Πtm≤t
dm
Ym
2
Both Kaplan-Meier and Nelson-Aalen estimators appear in Chapter 3.
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2.2 ANALYSIS OF LONGITIDINAL DATA
By longitudinal data, one usually refers to data measured repeatedly over time from the same
individual. Compared to the cross-sectional data, such data have an advantage of allowing
investigators to examine the average treatment effect over time. Mixed models [14, 15, 16]
is one of the most common method for the analysis of longitudinal data since it can take the
within-subject correlation into account.
There are three advantages of fitting mixed models. First, one model can estimate the
overall treatment effect, and the same model can also provide treatment effects at each
time point. Second, we can select the covariance structure for the repeated measurements.
Finally, the mixed models can handle missing data if the missing is not at random. Since
we adapt a mixed model approach in Chapter 4, we review the mixed models in following
sub-sections.
2.2.1 COVARIANCE STRUCTURE
A wide range of covariance structures are available. Here we selected to introduce three
most common structures: General, First-order Autoregressive, and Compound Symmetry.
For i = 1, ...n, let Yim be the repeatedly measured outcomes for the i
th subject at the mth
time point, m = 1, ...M . We define Yi to be the vector of observations from the i
th individual
and Ri to be the covariance matrix of Yi. Assuming the number of repeated measures is
four, the covariance structures are as follows
1. General
Ri =

σ21 θ12 θ13 θ14
θ21 σ
2
2 θ22 θ24
θ31 θ32 σ
2
3 θ34
θ41 θ42 θ43 σ
2
4
 ,
where θij=θji
2. First-order Auto Regressive
6
Ri =

σ2 σ2ρ σ2ρ2 σ2ρ3
σ2ρ σ2 σ2ρ σ2ρ2
σ2ρ2 σ2ρ σ2 σ2ρ
σ2ρ3 σ2ρ2 σ2ρ σ2
 .
3. Compound Symmetry
Ri =

σ2 θ θ θ
θ σ2 θ θ
θ θ σ2 θ
θ θ θ σ2
 .
where σ2 > θ
The first structure assumes that the variances at different time points are different as well
as the covariances. The advantage of this structure is that it requires a minimum assump-
tion about the covariance structure; however, the number of parameters can be large. For
example, the number of repeated measures is four, 10 parameters are to be estimated. The
second structure assumes that a relationship between the closer follow-ups has stronger cor-
relation than the further follow-ups. The variance over time is assumed to remain constant.
The most simple structure is the third one. The assumption is that the variance at each
time point is the same, and the covariance is set equal as well. This assumption may not
be realistic for some data, but it only requires to estimate two parameters compared to 10
parameters in the general structure.
2.2.2 RANDOM COEFFICIENTS MODEL
In general there are three categories of mixed models: random effects model, covariance
pattern model, and random coefficient model. For the random effect model, we assume
that certain effects are drawn from certain distributions and these effects add additional
variation to the data in addition to the residual variation. The covariance pattern model
allows us to fit fixed models with repeated measurements and a pattern of correlations
between observations is directly estimated. For the random coefficient model, we assume
7
that a covariate effect introduce additional variation. For example, if the intercept and
slopes are treated as random, these parameter themselves are assumed to have their own
distributions. Therefore, we can fit a model with subject-specific intercept and slopes. The
random coefficient mixed model can be expressed as follows
Yim = V
T
i α + βtim +H
T
i ηi + im, (2.1)
where Yim is the outcome vector, Vi is the fixed covariate vector, α is the parameter estimates
of the fixed covariates, β is the parameter estimate for random effects, tim indicates time, Hi
is the vector of random effects, and ηi’s are random vectors of parameters for each subject and
we assume that ηi is distributed as multivariate normal with mean 0 and variance-covariance
matrix G. We also assume im follows a Normal distribution with mean 0 and variance σ
2
e .
For details on random coefficient models, we refer the reader to Brown and Prescott [17]. In
Chapter 4, we adapt the random coefficients model to assess the effect of treatment regimes
on longitudinal outcome data in two-stage designs.
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2.3 MISSING DATA REVIEW
2.3.1 THREE PATTERNS OF MISSING DATA
According to Rubin [18], there are three different types of missing data mechanism: (1) Miss-
ing Completely at Random (MCAR), (2) Missing at Random (MAR), and (3) Not Missing
at Random (NMAR). First let us define G as the missing data indicator vector, Y be the
outcome matrix which includes observed outcome Yobs and missing outcome Ymis, and φ is
the unknown parameter associated with missing data. MCAR and MAR can be expressed
as
1. MCAR: f(G|Y, φ) = f(G|φ) for all Y and φ
2. MAR: f(G|Y, φ) = f(G|Yobs, φ) for all Ymis and φ,
In words, if missing data do not depend on the outcomes, the data are classified as MCAR.
If missing data depends on Yobs and φ, the data are considered as MAR, and if the missing
data depend on Ymis, the data are NMAR.
The NMAR data in a longitudinal study occur when subjects drop out from the study
because of their health-related outcomes. For example, if a subject receive a treatment at
baseline and if it is not effective (i.e. the outcomes continuously showed that he/she was not
responding to the treatment), the subject might choose not to participate in the study any
further. This type of dropout needs to be distinguished from random dropouts.
2.3.2 IMPUTATION METHODS
When missing data are NMAR, standard methods for analyzing continuous outcome data
such as GEE or Mixed Models produce biased results [19]. For such data, the pattern mixture
models [20] and the selection models [21] are the two most common methods. Since the
pattern mixture models have an advantage that we do not have to specify the distribution of
missing patterns, in this chapter, we focus on this approach. Since we selected to use random-
coefficient models in Section 5.3, we review random-coefficient pattern mixture models below.
The random-coefficient pattern mixture models can be fitted in three-steps: stratified the
9
data by the missing time points, fit a random coefficient model per stratified data, find the
estimate for the parameter of interest, and finally combine the estimates by multiplying with
the proportion of each missing data pattern. This model can be expressed as a factorized
likelihood. For ith subject where i = 1, ..n, let Yi be the vector of continuous outcomes, Gi is
the missing data indicator, Xi is the fixed covariate design matrix, and βi is the coefficient
of random effect. The joint likelihood of Yi, Gi and βi can be factorized as follows
[Yi, Gi, βi|Xi] = [Yi|Xi, βi, Gi][βi|Xi, Gi][Gi|Xi], (2.2)
where [Yi|Xi, βi, Gi] models the repeated outcomes stratified by missing data pattern,
[βi|Xi, Gi] models the within-subject variation due to random effect, and [Gi|Xi] models the
proportion of subjects in each missing data pattern.
Little [20] introduces one special type of random-coefficient pattern mixture models. It
is called Random-effect-dependent drop-out model, and we assume that the missing pattern
depends only on Xi and βi. In this model, the joint likelihood is simplified to
[Yi, Gi, βi|Xi] = [Yi|βi][βi|Xi, Gi][Gi|Xi]. (2.3)
and each component of the joint likelihood assumed to have the following distributions
[Yi|βi] ∼ NM
(
1 ti1
...
...
1 tiM

 βi0
βi1
 , σ2eI
)
,
[βi|Xi = x,Gi = g] ∼ N2(β(g)x ,Γ),
and
[Gi|Xi = x] ∼Multinomial(pix),
where βTi =(βi0, βi1) is the random intercept and slope, Xi is the fixed effect variable, such
as an indicator for treatment group, pix is the vector of proportions of subjects with X = x
within the subjects who fall in different missing patterns. Once pix and β
(g)
x are estimated,
the overall treatment effect can be combined as follows
E(β|Xi = x) =
M∑
g=1
pi(g)x β
(g)
x . (2.4)
In Chapter 5, we adapt the random coefficient drop-out model to assess the effects of treat-
ment regimes when the data are not missing at random.
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3.0 WEIGHTED KAPLAN-MEIER ESTIMATOR FOR TWO-STAGE
TREATMENT REGIMES
3.1 INTRODUCTION
Dynamic treatment regime is a set of rules that governs the assignment of time-varying
treatments based on intermediate response to prior treatments and covariates. For example,
in the treatment of depression, one two-stage dynamic treatment regime might consist of
the following sequence of rules: (a) start treating the patient with Citalopram (CIT), (a1)
evaluate the patient after 12 weeks of treatment with CIT, (b1) if the patient’s 16-item
Quick Inventory of Depressive Symptomatology (QIDS-C16) score is less than or equal to 5,
keep the patient on CIT for another 8 weeks (b2) otherwise, switch the patient to Buspirone
(BUP) for 12 weeks. A slightly different dynamic treatment regime might augment CIT
with BUP in the second stage when QIDS-C16 score after the first stage of treatment is not
below 5 (Figure 1). The goal in the treatment of depression is, for example, to reduce the
QIDS-C16 score. Therefore, one objective is to find the treatment regime that results in the
best possible outcome (e.g. minimum QIDS-C16 score) for a given subject. Knowing the
best patient-specific treatment regime beforehand allows the physician to choose the best
treatment options based on patient’s medical history. In practice, it is difficult to find the
best set of rules due to high inter-individual variability in patient characteristics. However,
if there are only a fixed number of regimes, then one might be interested in estimating the
effect of these regimes on overall outcome and compare the regimes based on corresponding
treatment effect. There are different statistical designs that allow estimation of regime-
specific treatment efficacy: (1) Single stage randomization design - randomize patients to all
possible treatment regimes upon entry into the trial, (2) Multiple separate trials for the first
11
Figure 1: Example of two two-stage regimes in chronic depression treatment
and second stages, and (3) Sequential Multiple Assignment Randomized Trials (SMART)
[22]. The first method is easy to conduct; however, it is expensive in terms of cost and
sample size while the second method renders issues related to patient comparability between
trials. Contrary to the first two methods, SMART has more attractive features: the design
randomizes eligible patients to available treatment options at each stage, allows estimation
of interaction effect between the first and second stage treatments, and perhaps requires
fewer subjects than that would have been required using either of the first two methods.
SMART designs are straightforward to implement. Patients entering into the trial are
randomized to the initial treatment options. Those proceeding to the next stage are ran-
domized to available treatment options based on their intermediate response to the initial
treatment, and so on. For example, suppose there are two treatment options A1 and A2 at the
first stage and two treatment options for both responders (B1 and B2) and non-responders
(B′1 and B
′
2) at the second stage. In SMART, patients are randomized to A1 or A2 followed
by another randomization at the second stage, to B1 or B2 if the patient is a responder or to
B′1 or B
′
2 if the patient is a non-responder. Number of treatment options in second stage may
vary between responders and non-responders. For example, in a leukemia trial described in
Stone et al. [1], patients not responding to the initial stage treatments were not treated
any further (see Section 6). The goal of SMART design is to estimate the effect of different
regimes of interest.
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In many chronic diseases such as leukemia and AIDS, the goal is to extend the length of
life (survival time). For analyzing survival data from SMAR trials, two methods have been
proposed in the literature, namely, marginal mean model approach [2], used by Lunceford et
al. [4] in the two-stage setting in the form of estimating equations, and a weighted risk set
(WRS) estimator proposed in Guo and Tsiatis [7]. The Lunceford et al. estimator (which
will be referred to as MM estimator) uses the method of inverse weighting [23]. The WRS
estimator is a modified Nelson-Aalen [13] estimator, where the method of inverse weighting
is used to create weighted counting processes. Both WRS and MM estimators were shown
to be asymptotically unbiased and normally distributed.
Kaplan-Meier estimator [11] is one of the most commonly used method of estimating
survival curves. It is tempting to apply this estimator to the subgroup of patients following
a particular regime. Wahed and Tsiatis [6] showed that such estimator is biased since it does
not account for the second randomization. In this article we propose an weighted version of
the standard Kaplan-Meier (SKM) estimator in order to account for the second randomiza-
tion in the two-stage SMART design. We follow Lunceford et al. [4] and Lokhnygina and
Helterband [9] to form weights based on the method of inverse probability weighting and
use them to construct weighted event and at-risk processes to be used in the Kaplan-Meier
estimator. We compare the properties of weighted Kaplan-Meier (WKM) estimator to that
of the SKM, MM, and the WRS estimators through simulation.
The article is organized as follows. In Section 3.2, we describe the set-up and notation
used throughout this article. Section 3.3 gives a review of existing methods: the MM and
WRS estimators. In Section 3.4, we introduce the weighted Kaplan-Meier estimator. The
results from a simulation study are reported in Section 3.5, followed by the application to a
leukemia data set in Section 3.6. We conclude with some remarks in Section 3.7.
3.2 SET-UP AND NOTATION
Consider treatment regimes consisting of two stages of treatments. A patient could receive A1
or A2 as initial treatment, and then upon response to the initial treatment could be treated
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Figure 2: Example of two-stage randomization design
with either B1 or B2. Patients not responding to the initial treatment could receive either B
′
1
or B′2 in the second stage. With these options, there are a total of eight treatment regimes,
namely, AjBkB
′
l, j, k, l = 1, 2 where AjBkB
′
l stands for “Treat with Aj followed by Bk if
respond, by B′l if otherwise.” Suppose Tjkl denote the survival time of a patient treated under
regime AjBkB
′
l. The goal is to estimate the survival distribution of the patient population
following a specific regime based on the data collected through a two-stage randomization
design. In other words, we are interested in estimating Sjkl(t) = Pr(Tjkl > t), for a given
t. In a two-stage randomization design (Figure 2) initially patients are randomized to two
treatment groups, namely, A1 and A2. The patients are then followed for intermediate
response. Those for whom a response is observed are then randomized to B1 or B2 and
non-responders are randomized to B′1 or B
′
2. Patients are followed until death, withdrawal,
or termination of the study.
Consider data from patients who are assigned to the A1 treatment group. For i = 1, 2, ..n,
the ith subject’s observed data can be presented as {TRi , Ri, RiZ1i, (1−Ri)Z2i, Vi,∆i} where
TRi is the time of intermediate response assessment, Ri is the indicator for response status to
the initial treatment A1(Ri=1 if the subject responded to A1; 0, otherwise), Z1i represents the
second treatment assignment for responders (Z1i=1 if the subject receives B1; 0, otherwise),
Z2i represents the second treatment assignment for non-responders (Z2i=1 if the subject
receives B′1; 0, otherwise), Vi is the time to death (Ti) or time to censoring (Ci) from initial
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randomization whichever occurs first, and ∆i is the indicator for complete (uncensored)
survival time, i.e, ∆i = I(Ci ≥ Ti).
Note that, for fixed j, k, and l, the survival time Tjkl is not observed for all patients
in the study. It is only observed for those who were on Aj, responded to Aj and received
Bk or did not respond to Aj and received B
′
l. Thus the challenge would be to estimate
the distribution of Tjkl based on the observed survival times which are subjected to right
censoring. We assume independent censoring, i.e.,
Ci ⊥ (Ti, X1i, Ri, Z1i, Z2i).
Let piB1 = Pr(Z1i = 1|Ri = 1), and piB′1 = Pr(Z2i = 1|Ri = 0) denote the randomization
probabilities for B1 and B
′
1 respectively. Assume that these randomization probabilities are
independent of observed data prior to the second randomization except for the intermediate
response status.
3.3 ESTIMATION
3.3.1 MARGINAL MEAN MODEL
Lunceford et al. [4] introduces three estimators based on estimating equations formed using
marginal mean model for regime-specific survival times. Their methods use the observations
that are consistent with a specific regime to estimate the regime-specific survival probabili-
ties; however, to account for the second randomization and right censoring, each observation
is weighted by the inverse probability of observing complete data. Consider the regime
A1B1B
′
1 and the observations from the A1 treatment group only. Patients receiving A1 and
receiving B1 after responding to A1, or B
′
1 after becoming resistant (non-responder) to A1 are
consistent with the treatment regime A1B1B
′
1. On the other hand, patients who received B2
after responding to A1 or B
′
2 after becoming resistant to A1 did not follow this regime. How-
ever these patients were equally eligible to receive B1 or B
′
1 as appropriate. Thus the data
from those who followed the regime A1B1B
′
1 need to be weighted for the loss of information
due to some patients receiving treatments other than the regime under consideration.
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Following the idea of inverse-probability weighting, each patient randomized to B1 then
receives a weight 1/piB1 (inverse of the randomization probability) and those randomized to
B′1 receives a weight of 1/piB′1 . Thus each observation within A1 arm receives a weight of
RiZ1i
piB1
+
(1−Ri)Z2i
piB′1
(3.1)
for the purpose of estimating quantities related to the regime A1B1B
′
1. We will denote this
by QA1B1B′1 .
Besides the information loss due to patients being assigned to a treatment group that
is not dictated by the regime, we also lose information due to some patients being right-
censored. To account for that Lunceford et al. [4] used another layer of inverse-probability
weights leading to the following weight for each observation:
∆i
K(Vi)
QA1B1B′1i
where K(t) = P (Ci ≥ t) where Ci is the censored time. But K(t) is unknown and needs to
be estimated from the data, leading to the estimated weight:
WA1B1B′1i =
∆i
Kˆ(Vi)
QA1B1B′1i
where Kˆ(Vi) is the product limit estimator of censoring survival distribution. Weights for
the other regimes can be constructed in a similar fashion.
With weights defined in this fashion, the MM estimator for the survival probability for
regime A1BkB
′
l is given by
ŜMMA1BkB′l(t) = 1− F̂
MM
A1BkB
′
l
(t)
where
F̂MMA1BkB′l(t) =
∑n
i=1WA1BkB′liI(Vi ≤ t)∑n
i=1WA1BkB′li
, k, l = 1, 2.
We note that this estimator uses only the observations belonging to the A1 treatment group.
But one could also impose another layer of weight for the first randomization (see the dis-
cussion section). Following Lunceford et al. [4], it can be shown that the MM estimator
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is asymptotically normally distributed with mean SA1BkB′l(t) and a variance that can be
estimated by
V̂ ar[SˆMMA1BkB′l(t)] = n
−1
[
n−1
n∑
i=1
∆i
Kˆ(Vi)
{QA1BkB′li(I(Vi ≤ t)− FˆMMA1BkB′l(t)}
2
+
∫ L
0
dN c(u)
Kˆ(u)Y (u)
Eˆ{LA1BkB′l(t, u)}2
]
where
Eˆ{LA1BkB′l(t, u)} = n−1
n∑
i=1
∆i[QA1BkB′li{I(Vi ≤ t)− FˆMMA1BkB′l(t)} − GˆA1BkB′l(t, u)]
2 I(Vi ≥ u)
Kˆ(Vi)
,
and
GˆA1BkB′l(t, u) = {nSˆ(u)}−1
n∑
i=1
∆iQA1BkB′li{I(Vi ≤ t)− FˆMMA1BkB′l(t)}
I(Vi ≥ u)
Kˆ(Vi)
,
where Sˆ(u) is the product limit estimator of survival distribution.
3.3.2 WEIGHTED RISK SET ESTIMATOR
Another method of estimation is to use Nelson-Aalen estimator. Since the observations that
are consistent with the regime A1BkB
′
l are not a random sample from the corresponding
population, again a weighted approach needs to be adapted. If everyone in the sample were
treated according to the regime A1BkB
′
l for fixed k and l, then the Nelson-Aalen estimator
[13] of SA1BkB′l(t) would have been defined as :
ŜA1BkB′l(t) = exp
{
−
∫ t
0
∑n
i=1 dNi(u)∑n
i=1 Yi(u)
}
,
where Ni(u) = I(∆i = 1, Ti ≤ u) is the indicator of whether the ith individual fails prior to
time u, and Yi(u) = I(Vi ≥ u) is the indicator of whether the subject is at risk at time u.
Since not all patients are treated according to the regime A1BkB
′
l, a weighted version of the
Nelson-Aalen estimator is calculated as follows:
ŜWRSA1BkB′l(t) = exp
{
−
∫ t
0
∑n
i=1QA1BkB′lidNi(u)∑n
i=1QA1BkB′liYi(u)
}
.
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Another version of this estimator with time-varying weight appeared in Guo and Tsiatis
[7] where the weight was allowed to depend on the time of response assessment. Since this
estimator is a special case of the estimator proposed in Guo and Tsiatis [7], we can follow the
argument therein to show that the WRS estimator is asymptotically normally distributed
with mean SA1BkB′l(t) and variance that can be estimated by:
V̂ ar(ŜWRSA1BkB′l(t)) = n
−1
{
ŜWRSA1BkB′l(t)
}2
σˆ2
where
σˆ2 = n−1
n∑
i=1
∫ t
0
QA1BkB′li
[
dNi(u)− Yi
{∑n
i=1QA1BkB
′
li
dNi(u)∑n
i=1QA1BkB
′
li
Yi(u)
}]
n−1
∑n
i=1QA1BkB′liYi(u)

2
.
3.4 PROPOSED METHOD
If everyone in the sample were treated with the regime A1BkB
′
l, the survival rate at time t
for the regime A1BkB
′
l could be estimated using the Kaplan-Meier estimator as follows:
ŜA1BkB′l(t) =
 1, t < t1Πtm≤t(1− dmYm ), t ≥ t1
where dm =
∑n
i=1 ∆iI(Vi = tm), Ym =
∑n
i=1I(Vi ≥ tm), tm,m = 1, 2, . . . , are the distinct
ordered failure times. However, as mentioned in the previous section, some patients will
potentially receive treatment inconsistent with the regime A1BkB
′
l, and we need to adjust
for the loss of these patients. Taking a similar approach to the MM and WRS estimators,
we propose the weighted Kaplan Meier estimator:
ŜA1BkB′l(t) =
 1, t < t1Πtm≤t(1− dwmY wm ) t ≥ t1
where dwm =
∑n
i=1 ∆iI(Vi = tm)QA1BkB′li , and Y
w
m =
∑n
i=1 I(Vi ≥ tm)QA1BkB′li . Thus we have
weighted the death process and the at risk process by the inverse of the probability of random-
ization. Xie and Liu [24] has proposed a similar method to construct weighted Kaplan-Meier
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estimator to adjust for covariate imbalance between randomized or non-randomized groups.
It can be shown that the WKM estimator is unbiased, and the proof is outlined in Section
3.4.1.
The variance of this estimator is obtained through slight modification of the Greenwood
formula [12] as suggested in Xie and Liu [24] as follows:
V̂ ar[ŜA1BkB′l(t)] = [ŜA1BkB′l(t)]
2
∑
m:tm≤t
1− sˆA1BkB′lm
M̂A1BkB′lm ŝA1BkB′lm
,
where
M̂A1BkB′lm =
(
n∑
i=1
QA1BkB′liI(Vi ≥ tm)
)2 / n∑
i=1
{
QA1BkB′liI(Vi ≥ tm)
}2
,
and ŝA1BkB′lm = 1−dwm/Y wm ,m = 1, 2, .... The derivation of this variance is outlined in Section
3.4.2.
3.4.1 UNBIASSEDNESS OF Sˆ(t)
We follow Xie and Liu [24] to show the unbiasedness of weighted Kaplan-Meier estimator.
First, we define sA1BkB′lm = SA1BkB′l(tm)/SA1BkB′l(tm−1) to be the probability of survived
beyond time tm given treat the patient has survived until tm−1, and unbiased estimator
of which is given by sˆA1BkB′lm = 1 − dwm/ywm. The proof of unbiasedness depends on the
assumption that at any time point tm, there is a positive number of subjects at risk for those
who followed a specific regime, e.g. A1B1B
′
1.
Em(1− sˆA1B1B′1m) = Em
[∑n
i=1 ∆iI(Vi = tm)QA1B1B′1i∑n
i=1 I(Vi ≥ tm)QA1B1B′1i
]
= Em
{
Em
[∑n
i=1 ∆iI(Vi = tm)QA1B1B′1i∑n
i=1 I(Vi ≥ tm)QA1B1B′1i
∣∣Z1i, Z2i, Ri, i, s.t. Vi ≥ tm]}
= Em
[
(1− sA1B1B′1m)
∑n
i=1 I(Vi ≥ tm)QA1B1B′1i∑n
i=1 I(Vi ≥ tm)QA1B1B′1i
]
= 1− sA1B1B′1m
where Em indicates a conditional expectation given the information up to time tm. The
conditional expected values for the other regimes, Em(1− sˆA1BkB′lm) with k, l = 1, 2, can be
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constructed similarly with the regime-specific assumption. Now using the method of suc-
cessive conditional expectations, we show that E(SˆA1BkB′l(t))=SA1BkB′l(t). For convenience,
we use a simplified notation and let QA1BkB′l = Q, SˆA1BkB′l(t) ≡ Sˆ(t), SA1BkB′l(t) ≡ S(t),
sˆA1BkB′lm ≡ sˆm, and sA1BkB′l(t) ≡ s(t). Let tq be the maximum observed death time prior to
t, then Sˆ(t)=
∏q
m=1 sˆm and we have
E[Sˆ(t)] = E[sˆ1...sˆq−1Eq(sˆq)] = E[sˆ1...sˆq−1sq]
= sqE[sˆ1...sˆq−2Eq(sˆq−1)] = ...
= s1...sq−1sq = S(t).
Thus, the WKM is an unbiased estimator.
3.4.2 VARIANCE OF Sˆ(t)
Let V arm denotes the variance conditional on information up to but not including time tm.
Then,
V arm(sˆm) = V arm(1−
∑n
i=1 ∆iI(Vi = tm)Qi∑n
i=1 I(Vi ≥ tm)Qi
)
=
∑n
i=1 V arm(∆iI(Vi = tm)Qi)
(
∑n
i=1 I(Vi ≥ tm)Qi)2
=
∑n
i=1 I(Vi = tm)Q
2
iV arm(∆i : I(Vi = tm))
(
∑n
i=1 I(Vi ≥ tm)Qi)2
=
∑n
i=1 I(Vi ≥ tm)Q2i sm(1− sm)
(
∑n
i=1 I(Vi ≥ tm)Qi)2
=
sm(1− sm)
Mm
(3.2)
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where 1/Mm is
∑n
i=1 I(Vi ≥ tm)Qi2/(
∑n
i=1 I(Vi ≥ tm)Qi)2. Now,
E[Sˆ(t)]2 =
q∏
m=1
Em[sˆ
2
m]
=
q∏
m=1
(Em(sˆ
2
m) + V arm(sˆm))
=
q∏
m=1
(
s2m +
sm(1− sm)
Mm
)
using (3.2)
=
q∏
m=1
(
s2m + s
2
m
1− sm
Mmsm
)
=
q∏
m=1
s2m
(
1 +
1− sm
Mmsm
)
= s21...s
2
q
l∏
m=1
(
1 +
1− sm
Mmsm
)
= (S(t))2
q∏
m=1
(
1 +
1− sm
Mmsm
)
.
Finally, V ar[Sˆ(t)] can be derived as
V ar[Sˆ(t)] = (S(t))2
q∏
m=1
(
1 +
1− sm
Mmsm
)
− S2(t).
≈ (S(t))2
q∑
m=1
1− sm
Mmsm
(3.3)
The assumption here is that maxiI(Vi ≥ tm)Qi/
∑n
i=1 I(Vi ≥ tm)Qi → 0 so that we can
ignore terms of order greater than M−1m in (3.3).
3.5 SIMULATION STUDY
A simulation study was conducted to examine the performance of the proposed estimator
and its large sample properties. The results were compared to those of the other estimators.
The data were generated following the two-stage SMART design with two initial treatments
and two separate pairs of second-stage treatments depending on the outcome of the initial
treatment, as shown in Figure 2. Since the data from subjects who were randomized to A1
21
are independent of those who received A2, only A1 treatment path was considered for the
simulation.
The proposed and existing estimators were examined in three different scenarios. In the
first scenario, we generated the datasets with an equal randomization rate for the second
stage treatments for both responders and non-responders. Using the notation in Section 2,
Z1i and Z2i were drawn from a Bernoulli distribution with a mean of 0.5. In the second
scenario, Z1i and Z2i were drawn from a Bernoulli distribution with a mean of 0.3 and 0.5,
respectively. Finally, in the third scenario, all responders receive the same second stage
treatment (B1) while the non-responders are equally randomized to one of the two second
stage treatments. Therefore, Z1i was set to 1 for all responders, and Z2i was drawn from a
Bernoulli distribution with a mean of 0.5.
We generated 2000 datasets with 200 and 500 observations in each, and 40% and 70%
response rates were selected to represent the lower and higher response rates. Each dataset
contained the variables TR, R, Z1, Z2, ∆, and V as described in Section 2. For the i
th patient,
the time to response to the initial treatment (TRi ) was generated from an Exponential(0.7)
distribution, restricted at 2 years. For convinience, the time to not respond (TNRi ) is set
equal to TRi . The time to death from the second randomization (T
∗
A1Bki
or T ∗A1B′li , k, l = 1, 2)
was drawn from a Uniform distribution with a range of 0 to (1+0.5TRi )*1.5 for the sequence
of treatments A1B1, 0 to (1+0.5T
R
i )*1 for the A1B2 treatment, 0 to (0.75+0.25T
NR
i )*0.75 for
the A1B
′
1 treatment, and 0 to (0.75+0.25T
NR
i )*0.5 for the A1B
′
2 treatment. In the absence
of censoring, the observed survival time is then Ti = RiT
R
i +Ri[Z1iT
∗
A1B1i
+(1−Z1i)T ∗A1B2i ]+
(1 − Ri)TNRi + (1 − Ri)[Z2iT ∗A1B′1i + (1 − Z2i)T
∗
A1B′2i
]. The time to censoring (Ci) is created
as a sum of TRi and a random value generated from a Uniform distribution between 0 and
(5− TRi ) years. Finally, the observed time to event (Vi) was set to a minimum of Ti and Ci,
and the death indicator (∆i) was set to 1 if Ti was less than Ci, 0 otherwise. In all scenarios,
the total percentage of censoring was 29.5% for the 40% response rate, and 37.4% for the
70% rate.
Although, in the first and second scenario, there were 4 possible regimes, we only present
the results for regimes A1B1B
′
1 and A1B1B
′
2. The results follow the same trend for the
other regimes. Table 1 provides the results for simulation scenario 1, where responders and
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non-responders were assigned to the second stage treatments with equal probability. For
this case, all four estimators were approximately unbiased with similar standard errors. The
relative bias varied from 0 to 0.06. However the coverage probabilities for the 95% confident
interval were closest to the nominal level for the WKM estimator most of the time, followed
by the SKM estimator. With the increase in sample size from 200 to 500, both relative bias
and the standared errors were reduced with improvement in the coverage probability.
Table 2 summarizes the results for simulation scenario 2, where the second stage ran-
domization rates were set to be unequal for the responders and non-responders. The three
estimators (WKM, WRS, and MM) performed very similarly, and the estimates in this sce-
nario were very close to the ones in scenario 1. The standard errors increased naturally for
covering the higher percentage of loss due to the lower randomization rate to B1. The SKM
estimator, however, produced estimates with higher relative bias and significantly lower cov-
erage rates compared to scenario 1. The differences in the results were more obvious for the
regime A1B1B
′
2, for which the relative bias was as high as 0.07 and the coverage probability
for 95% confidence interval as as low as 85.6%.
Table 3 lists the results from simulation scenario 3, where the responders received the
same second stage treatment, but the non-responders were equally randomized to one of the
two second stage treatments. Again the three inverse-probability-weighted methods (WKM,
WRS, and MM) provided very close estimates; however, the standard errors for WKM and
WRS were slightly smaller than those for the MM estimator. The coverage rates for the
WKM and WRS estimators were lower compared to the rates for the MM estimator. The
SKM performed quite poorly, indicated by a range of relative bias between 0.04 to 0.17. The
coverage rate dropped dramatically and the highest rate was only 75.9%.
In conclusion, the simulation studies showed that the WKM estimator is approximately
unbiased in three different randomization scenarios. The performance of the WKM was very
similar to the other two existing estimators MM and WRS. The SKM, on the other hand,
was only unbiased when the second randomization rate was equal between responders and
non-responders. When the SKM was applied to the scenarios with the unequal random-
ization rates, the relative bias increased significantly. This result showed that the modified
survival estimators with the inverse-probability weighting method are necessary to estimate
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the survival distribution for the multiple stage design with unequal randomization rates.
3.6 ANALYSIS OF CALGB DATA
The four estimators were applied to a dataset from Cancer and Leukemia Group B (CALGB).
The study was a two-stage double-blind placebo-controlled randomized clinical trial, and a
total of 388 elderly patients with acute myelogenous leukemia were enrolled. At the first
stage, 193 patients were randomized to one of the two initial treatments GM-CSF (A1),
and 195 were randomized to the Placebo group (A2). At the second stage, 37 GM-CSF
responders and 45 Placebo responders were randomized to the maintenance therapy I (B1),
and 42 GM-CSF responders and 45 Placebo responders were randomized to the maintenance
therapy II (B2). Since the non-responders (114 patients in GM-CSF, and 105 in Placebo)
were not randomized at the second stage, the weight function from (3.1) for the regime A1Bk
is written as
QA1Bki =
RiZ1i
piBk
+ (1−Ri), k = 1, 2.
Thus there are a total of four treatment regimes for this study: (a) Treat with GM-CSF
and a standard chemotherapy, follow by the maintenance therapy I if respond to the initial
treatment (b) Treat with GM-CSF and a standard chemotherapy, follow by the mainte-
nance therapy II if respond to the initial treatment, (c) Treat with Placebo and a standard
chemotherapy, follow by the maintenance therapy I if respond to the initial treatment, and
(d) Treat with Placebo and a standard chemotherapy, follow by the maintenance therapy
II if respond to the initial treatment. All four methods discussed in previous sections were
applied to the CALGB 8923 data, and the survival distributions for the four regimes were
estimated. The results are shown in Figure 3.
Figure 3 shows that the three methods (WKM, MM, and WRS) provide very similar es-
timates for the survival curve under different regimes. However, the SKM estimator provides
estimates which were always lower to those obtained from other methods. Figure 4 provides
the survival estimates for four regimes in CALGB data using WKM approach. It is evident
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Table 1: Simulation Scenario 1: Even Second Stage Randomization Rate of
P(Z1)=0.5 and P(Z2)=0.5. Monte Carlo Mean, Standard Error, Relative Bias, and
Coverage Rate (based on 95% C.I.) for estimating survival probabilities at time t for the two
regimes A1B1B
′
1 and A1B1B
′
2. n=200 and 500, P(response)=0.4 and 0.7, and t=0.5 and 1.0
year.
Regime A1B1B
′
1 Regime A1B1B
′
2
n t P(r)MethodS(t) MC Mean Relative CoverageS(t) MC Mean Relative Coverage
(SE) Bias Rate(%) (SE) Bias Rate(%)
2000.5 0.4 SKM 0.81 0.81(0.039) 0.00 92.3 0.75 0.75(0.043) 0.00 92.8
WKM 0.81(0.039) 0.00 92.3 0.75(0.043) 0.00 92.8
WRS 0.81(0.039) 0.00 91.7 0.75(0.043) 0.00 92.5
MM 0.81(0.039) 0.00 92.7 0.75(0.043) 0.00 92.8
0.7 SKM 0.86 0.86(0.035) 0.00 92.8 0.83 0.83(0.038) 0.00 93.3
WKM 0.86(0.035) 0.00 92.8 0.83(0.038) 0.00 93.3
WRS 0.86(0.035) 0.00 92.5 0.83(0.037) 0.00 93.2
MM 0.86(0.035) 0.00 92.7 0.83(0.038) 0.00 93.1
1.0 0.4 SKM 0.49 0.51(0.051) 0.04 92.9 0.46 0.47(0.051) 0.02 93.6
WKM 0.51(0.051) 0.04 92.9 0.47(0.051) 0.02 93.7
WRS 0.52(0.051) 0.06 92.5 0.48(0.051) 0.04 93.3
MM 0.51(0.051) 0.04 92.5 0.47(0.051) 0.02 93.1
0.7 SKM 0.60 0.62(0.050) 0.03 94.7 0.58 0.60(0.050) 0.03 94.3
WKM 0.62(0.050) 0.03 94.7 0.60(0.050) 0.03 94.3
WRS 0.62(0.050) 0.03 94.2 0.60(0.050) 0.03 93.7
MM 0.61(0.050) 0.02 94.1 0.59(0.050) 0.02 94.0
5000.5 0.4 SKM 0.81 0.81(0.025) 0.00 92.1 0.75 0.75(0.027) 0.00 93.2
WKM 0.81(0.025) 0.00 92.8 0.75(0.027) 0.00 93.2
WRS 0.81(0.025) 0.00 92.1 0.75(0.027) 0.00 93.1
MM 0.81(0.025) 0.00 92.3 0.75(0.028) 0.00 93.2
0.7 SKM 0.86 0.86(0.022) 0.00 93.9 0.83 0.83(0.024) 0.00 95.0
WKM 0.86(0.022) 0.00 93.9 0.83(0.024) 0.00 95.0
WRS 0.86(0.022) 0.00 93.7 0.83(0.024) 0.00 95.0
MM 0.86(0.022) 0.00 93.8 0.83(0.024) 0.00 94.8
1.0 0.4 SKM 0.49 0.51(0.032) 0.04 90.6 0.46 0.47(0.032) 0.02 91.8
WKM 0.51(0.032) 0.04 90.6 0.47(0.032) 0.02 91.8
WRS 0.51(0.032) 0.04 90.2 0.47(0.032) 0.02 91.4
MM 0.51(0.033) 0.04 90.9 0.47(0.033) 0.02 92.0
0.7 SKM 0.60 0.61(0.032) 0.02 92.3 0.58 0.59(0.032) 0.02 93.5
WKM 0.61(0.032) 0.02 92.3 0.59(0.032) 0.02 93.5
WRS 0.61(0.031) 0.02 92.0 0.59(0.032) 0.02 93.2
MM 0.61(0.032) 0.02 92.7 0.59(0.032) 0.02 93.4
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Table 2: Simulation Scenario 2: Uneven Second Stage Randomization Rate of
P(Z1)=0.3 and P(Z2)=0.5. Monte Carlo Mean, Standard Error, Relative Bias, and
Coverage Rate (based on 95% C.I.) for estimating survival probabilities at time t for the two
regimes A1B1B
′
1 and A1B1B
′
2. n=200 and 500, P(response)=0.4 and 0.7, and t=0.5 and 1.0
year.
Regime A1B1B
′
1 Regime A1B1B
′
2
n t P(r)MethodS(t) MC Mean Relative CoverageS(t) MC Mean Relative Coverage
(SE) Bias Rate(%) (SE) Bias Rate(%)
2000.5 0.4 SKM 0.81 0.79(0.044) 0.02 93.8 0.75 0.72(0.049) 0.04 93.1
WKM 0.81(0.044) 0.00 93.6 0.75(0.049) 0.00 94.3
WRS 0.81(0.044) 0.00 93.3 0.75(0.049) 0.00 94.1
MM 0.81(0.042) 0.00 92.1 0.75(0.047) 0.00 92.9
0.7 SKM 0.86 0.84(0.043) 0.02 94.0 0.83 0.80(0.047) 0.04 94.0
WKM 0.86(0.042) 0.00 93.8 0.83(0.046) 0.00 94.9
WRS 0.86(0.042) 0.00 93.2 0.83(0.046) 0.00 94.9
MM 0.86(0.040) 0.00 91.8 0.83(0.043) 0.00 93.9
1.0 0.4 SKM 0.49 0.48(0.056) 0.02 93.1 0.46 0.43(0.055) 0.07 89.7
WKM 0.51(0.059) 0.04 93.5 0.47(0.059) 0.02 93.3
WRS 0.52(0.058) 0.04 93.5 0.48(0.059) 0.04 92.9
MM 0.51(0.057) 0.06 92.5 0.47(0.058) 0.02 93.1
0.7 SKM 0.60 0.58(0.059) 0.03 93.4 0.58 0.55(0.060) 0.05 90.8
WKM 0.61(0.061) 0.02 93.9 0.59(0.062) 0.02 94.8
WRS 0.62(0.060) 0.03 93.7 0.60(0.062) 0.03 94.4
MM 0.61(0.059) 0.02 93.2 0.59(0.060) 0.02 93.7
5000.5 0.4 SKM 0.81 0.79(0.028) 0.02 93.5 0.75 0.72(0.031) 0.04 88.9
WKM 0.81(0.028) 0.00 94.2 0.75(0.031) 0.00 94.4
WRS 0.81(0.028) 0.00 94.0 0.75(0.031) 0.00 94.4
MM 0.81(0.027) 0.00 93.0 0.75(0.030) 0.00 92.8
0.7 SKM 0.86 0.84(0.028) 0.02 93.4 0.83 0.80(0.030) 0.04 88.2
WKM 0.86(0.027) 0.00 94.8 0.83(0.029) 0.00 96.4
WRS 0.86(0.027) 0.00 94.7 0.83(0.029) 0.00 96.3
MM 0.86(0.026) 0.00 93.4 0.83(0.027) 0.00 94.7
1.0 0.4 SKM 0.49 0.47(0.035) 0.04 92.0 0.46 0.43(0.035) 0.07 85.6
WKM 0.51(0.037) 0.04 92.7 0.47(0.037) 0.02 93.1
WRS 0.51(0.037) 0.04 92.2 0.47(0.037) 0.02 92.8
MM 0.51(0.037) 0.04 92.2 0.47(0.037) 0.02 92.6
0.7 SKM 0.60 0.57(0.038) 0.05 89.2 0.58 0.55(0.038) 0.05 85.9
WKM 0.61(0.039) 0.02 94.3 0.59(0.039) 0.02 94.9
WRS 0.61(0.039) 0.02 93.9 0.59(0.039) 0.02 94.6
MM 0.61(0.038) 0.02 93.3 0.59(0.038) 0.02 93.8
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Table 3: Simulation Scenario 3: Uneven Second Stage Randomization Rate of
P(Z1)=1.0 and P(Z2)=0.5. Monte Carlo Mean, Standard Error, Relative Bias, and
Coverage Rate (based on 95% C.I.) for estimating survival probabilities at time t for the two
regimes A1B1B
′
1 and A1B1B
′
2. n=200 and 500, P(response)=0.4 and 0.7, and t=0.5 and 1.0
year.
Regime A1B1B
′
1 Regime A1B1B
′
2
n t P(r)MethodS(t) MC Mean Relative CoverageS(t) MC Mean Relative Coverage
(SE) Bias Rate(%) (SE) Bias Rate(%)
2000.5 0.4 SKM 0.81 0.84(0.031) 0.04 75.9 0.75 0.80(0.034) 0.07 65.2
WKM 0.81(0.035) 0.00 90.3 0.75(0.038) 0.00 91.4
WRS 0.81(0.035) 0.00 89.9 0.75(0.038) 0.00 91.4
MM 0.81(0.037) 0.00 91.8 0.75(0.041) 0.00 92.8
0.7 SKM 0.86 0.88(0.025) 0.02 79.4 0.83 0.86(0.026) 0.04 69.0
WKM 0.86(0.028) 0.00 90.7 0.83(0.030) 0.00 89.9
WRS 0.86(0.028) 0.00 90.9 0.83(0.030) 0.00 89.9
MM 0.86(0.030) 0.00 92.3 0.83(0.033) 0.00 92.1
1.0 0.4 SKM 0.49 0.57(0.043) 0.16 54.6 0.46 0.54(0.043) 0.17 46.3
WKM 0.51(0.044) 0.04 90.8 0.47(0.044) 0.02 92.6
WRS 0.52(0.044) 0.06 90.2 0.48(0.044) 0.04 92.3
MM 0.51(0.046) 0.04 91.8 0.47(0.046) 0.02 93.2
0.7 SKM 0.60 0.66(0.037) 0.05 64.7 0.58 0.65(0.038) 0.12 59.6
WKM 0.62(0.039) 0.02 91.8 0.60(0.039) 0.03 91.9
WRS 0.62(0.039) 0.02 91.5 0.60(0.039) 0.03 91.7
MM 0.62(0.041) 0.02 93.2 0.60(0.042) 0.03 93.5
5000.5 0.4 SKM 0.81 0.84(0.020) 0.04 57.0 0.75 0.80(0.022) 0.07 34.6
WKM 0.81(0.022) 0.00 90.1 0.75(0.024) 0.00 90.3
WRS 0.81(0.022) 0.00 89.9 0.75(0.024) 0.00 90.2
MM 0.81(0.023) 0.00 92.5 0.75(0.026) 0.00 92.3
0.7 SKM 0.86 0.88(0.016) 0.02 65.8 0.83 0.86(0.017) 0.04 44.1
WKM 0.86(0.018) 0.00 90.8 0.83(0.019) 0.00 91.4
WRS 0.86(0.018) 0.00 90.7 0.83(0.019) 0.00 91.4
MM 0.86(0.019) 0.00 92.8 0.83(0.021) 0.00 94.3
1.0 0.4 SKM 0.49 0.57(0.027) 0.16 18.4 0.46 0.54(0.027) 0.17 11.6
WKM 0.51(0.028) 0.04 88.0 0.47(0.028) 0.02 88.5
WRS 0.51(0.028) 0.04 87.7 0.47(0.028) 0.02 88.1
MM 0.51(0.029) 0.04 90.6 0.47(0.029) 0.02 89.0
0.7 SKM 0.60 0.66(0.024) 0.10 35.4 0.58 0.64(0.024) 0.10 26.9
WKM 0.61(0.025) 0.02 89.4 0.59(0.025) 0.02 90.7
WRS 0.61(0.025) 0.02 89.0 0.59(0.025) 0.02 90.3
MM 0.61(0.026) 0.02 90.9 0.59(0.026) 0.02 92.3
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that none of the regime is clearly superior to the other three regimes.
3.7 DISCUSSION
We proposed the weighted Kaplan-Meier estimator to estimate the survival distribution for
different treatment regimes from SMART designs. The inverse of the second stage random-
ization rate was used as a weight in order to account for the loss of information from those
who were randomized to a treatment other than the regime dictated. One advantage of
using this method is that the implementation is straightforward compared to the existing
methods. In addition, the method can provide survival estimates at time points where there
are only censored cases in the risk set. In contrast, the MM method provides zero as the
survival estimate after the last event case is observed. Therefore, when one is interested in
finding the survival rates at the later stage of follow-up times, the weighted Kaplan-Meier
method may be more appropriate.
As briefly mentioned in Section 3.3.1, it is possible to add another layer of weight for the
first randomization. In this case, patients receiving initial treatment, for example, A1 would
additionally be weighted by 1/piA1i, where piA1i can be estimated by a propensity score for
receiving the treatment A1. The score may be calculated using a logistic regression model
including the covariate information. For estimating quantities related to the regime A1B1B
′
1,
the weight in (3.1) would be changed to
Q∗A1B1B′1 =
Xi
piA1i
QA1B1B′1 ,
where Xi = 1, if patient receives A1; 0, otherwise. This would allow gaining efficiency for
the estimators by accounting for the information loss due to some patients receiving A2 at
the beginning.
Further research in this area includes generalizing the WKM estimator to account for
the variable intermediate response time.
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Figure 3: SKM, WKM, MM, and WRS survival estimates for four regimes in CALGB study
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Figure 4: WKM survival estimates for four regimes in CALGB study
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4.0 ASSESSING THE EFFECT OF TREATMENT REGIMES ON
LONGITUDINAL OUTCOME DATA FROM SEQUENTIALLY
RANDOMIZED DESIGNS
4.1 INTRODUCTION
In biomedical studies, it is common to apply multiple treatments in sequence to improve
patients’ quality of life. For example, the REVAMP (Research Evaluating the Value of
Augmenting Medication with Psychotherapy) study [25] adopted a two-stage study design
to assess the efficacy of combining pharmacotherapy and psychotherapy for the chronically
depressed subjects. The study recruited a total of 808 subjects with chronic forms of ma-
jor depression disorder (MDD) between 2003 and 2006. The study design is illustrated in
Figure 5. At the initial stage, subjects received one of four treatments: Sertaline (SERT),
Escitalopram (EcCIT), Burpropion (BUP-SR), and Venlafaxine (VLF-XR). The treatment
assignment at this stage was done by REVAMP study physicians based on an algorithm
which took into account the subject’s treatment history. The treatment assignment was
deterministic, for example, if a subject had never failed two adequate trials of Selective
Serotonin Reuptake Inhibitors (SSRIs) and had no history of SERT failure in the past, this
subject was assigned to the treatment with SERT. Each subject was followed for at most
12 weeks during which 24-item Hamilton Rating Scale of Depression (HRSD24) score was
collected at 2 weeks interval. During the 6 to 12 follow-up visits, if a subject’s HRSD24 score
was reduced 60% or more from the study entry to a value less than 8, and the subject did
not meet the diagnostic and statistical manual of mental disorders 4th edition MDD criteria
for two consecutive visits, the subject was considered to be a responder to the corresponding
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Figure 5: REVAMP study design
initial treatment. If the HRSD24 score was only reduced less than 30%, and the subject did
not meet the DSM-IV MDD criteria for two consecutive visits between week 6 to 12, the
subject was considered to be a non-responder. If the subject did not meet the criteria for
either a responder or a non-responder, then the subject was classified as a partial responder.
At the second stage, the responders to the initial treatment moved to the follow-up stage,
during which they continued to receive the same initial treatment for another 12 months
with monthly follow-up visits. The partial responders and non-responders were randomly
assigned to one of the three treatment options:(1) Medication change only (MC), (2) Med-
ication change and cognitive behavioral analysis system of psychotherapy (MC/CBASP),
and (3) Medication change and supportive psychotherapy (MC/SP). Details of the medica-
tion changes can be found in Trivedi [25]. The randomization rates for the three treatment
options were 20%, 40%, and 40%, respectively. Similar to the initial stage, subjects were
followed for 12 weeks, and the HRSD24 score was measured repeatedly at two weeks interval.
The aims of the REVAMP study were to compare the efficacy of adding psychotherapy
to a medication change versus changing medication alone (in chronic depressives with partial
response or non-response to an initial antidepressant medication), and to test the efficacy of
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the CBASP as an augmentation regime by comparing it to the SP. The study design allows
twelve treatment regimes. In general, a treatment regime consists of an initial treatment, an
intermediate response, and a second stage treatment. For the initial treatment X and the
second stage treatment Y , the policy X−Y can be defined as “Treat with initial treatment X,
if respond continue the same treatment, otherwise switch to second stage treatment Y .” For
example, consider subjects treated with SERT at the initial stage. There are three possible
treatment regimes these subjects could follow: (1) Treat with SERT, if respond continue
SERT, otherwise change or add medication, (2) Treat with SERT, if respond continue SERT,
otherwise treat with the CBASP, (3) Treat with SERT, if respond continue SERT, otherwise
treat with the SP. Nine other treatment regimes can be constructed similarly with those who
were treated with EcCIT, BUP-SR, and VLF-XR.
Standard methods for estimating treatment effect from longitudinal outcome data include
generalized estimating equations [26, 27], generalized linear and mixed models [14, 15, 16].
The REVAMP study uses the mixed models for estimating the treatment effect for the
randomized treatment groups. In our situation, the treatment regimes consist of sequences of
treatments applied conditionally on intermediate response. Besides, one subject can belong
to more than one regimes. For example, patients responding to SERT belongs to three
different regimes, namely, SERT-MC, SERT-MC/CBASP, and SERT-MC/SP. Therefore, it
is not as straightforward to estimate the effect of an regime or compare different regimes using
standard longitudinal data analysis techniques. Statistical inference on treatment regimes
using a summary outcome measure has been well-studied in the literature. For example,
estimation of a mean response based on observational longitudinal data are proposed in
Murphy, van der Laan and Robins [2] and Murphy [3]. Methods for survival outcomes were
considered in Lunceford et al. [4], Wahed and Tsiatis [5, 6], Guo and Tsiatis [7], Hernan et
al. [8], and Lokhnygina and Helterbrand [9]. Thall et al. [10] adapts a Bayesian approach
to model the time to failure and compare two-stage adaptive treatment regimes. However,
statistical methods for assessing the effect of treatment regimes on repeated measures data
are not well-developed. In this article, we propose two methods for estimating treatment
regime effects from longitudinal outcome data. We also investigate the use of Wald tests in
comparing several treatment regimes.
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In Section 4.2, we describe the notation, data structure, model, and assumptions. Sec-
tion 4.3 describes the estimation procedures. Hypothesis testing for comparing the treatment
regimes is described in Section 4.4. The results from simulation studies are reported in Sec-
tion 4.5, followed by an application to the REVAMP study data in Section 4.6. The article
is concluded with some discussions in Section 4.7.
4.2 DATA STRUCTURE AND MODELS
4.2.1 SETUP
We start with a generalized version of the REVAMP study design, where responders to initial
treatments are also randomized to further treatments (possibly to maintain the response).
In cases where responders are not randomized further such as the REVAMP study, we can
envision a single second stage treatment for responders. Also, for simplicity, we assume that
there are two treatment options at each stage. Generalization to more than two treatments
will be straightforward. We depict such a design in Figure 6. Let the two initial treatments
be denoted by A1 and A2, and the two sets of second stage treatments by B1 and B2 for
the responders, and B′1 and B
′
2 for the non-responders. There are a total of eight treatment
regimes in this setting, namely, AjBkB
′
l, j, k, l = 1, 2, where AjBkB
′
l stands for “Treat with
Aj followed by Bk if respond, by B
′
l otherwise.” For each individual i, we can envision a
number of variables described as follows. For j, k, l = 1, 2 and m = 1, 2, . . . ,M , let us define,
Ri(Aj) = response status if the i
th individual receives initial treatment Aj; Yim(AjBk) =
outcome (e.g., HRSD24 score) measured at time tim if the i
th individual receives Bk following
a response to the initial treatment Aj; Yim(AjB
′
l) = outcome (e.g., HRSD24 score) measured
at time tim if the ith individual receives B
′
l after becoming a non-responder to the initial
treatment Aj; Vi= vector of baseline covariates such as age and sex; Li(Aj)= Vector of
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Figure 6: Example of two-stage design
variables collected during the initial treatment stage for the ith individual receiving initial
treatment Aj, e.g. time to initial response and minimum HRSD24 score observed during the
initial treatment phase.
Notice that in practice not all the variables defined above could be observed for each
individual. For example, if a patient actually receives A1, then we would not be able to
observe R(A2) for that patient. If a patient receives A1, responds initially and then receives
B1, we will not be able to observe the variables Y (A1B2), Y (A1B
′
1), Y (A1B
′
2), Y (A2B1),
Y (A2B2), Y (A2B
′
1), or Y (A2B
′
2). These variables are referred to as counterfactuals [28]. We
will use them to formulate the estimand of interest. With these notation, we can now define
the outcome under the regime AjBkB
′
l as
Yim(AjBkB
′
l) = Ri(Aj)Yim(AjBk) + {1−Ri(Aj)}Yim(AjB′l). (4.1)
The goal is to estimate the effect of the treatment regime AjBkB
′
l, j, k, l = 1, 2 on the changes
in outcome Y over time adjusting for other baseline and first-stage patient characteristics.
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4.2.2 THE MODEL
We postulate the model
E [Yim(AjBkB
′
l)|Vi, Li(Aj), tim] = V Ti α(AjBkB′l)+LTi (Aj)γ(AjBkB′l)+β(AjBkB′l)tim (4.2)
to assess the effect of the treatment regime AjBkB
′
l on the changes in outcome Y over
time adjusting for baseline covariate vector Vi and the vector of covariates from the initial
stage Li(Aj). However, as mentioned earlier, not all patients were treated according to
this regime. Therefore, the challenge would be to estimate the parameters θ(AjBkB
′
l) =
{α(AjBkB′l), γ(AjBkB′l), β(AjBkB′l)} for all j, k, l = 1, 2 based on the observed data. Note
that the actual interest is in estimating and comparing the parameters β(AjBkB
′
l), j, k, l =
1, 2, while treating {α(AjBkB′l), γ(AjBkB′l)} j, k, l = 1, 2 as nuisance. Also we note that
in model (4.2) the effect of baseline covariate on the response Y is allowed to vary across
regimes and hence the notation α(AjBkB
′
l). If we denote by V
∗ the vector of covariates
formed by stacking the baseline and first stage covariates, and time, i.e.,
V ∗i = [V
T
i , L
T
i (Aj), tim]
T ,
model (4.2) could be simplified as
E [Yim(AjBkB
′
l)|V ∗i ] = V ∗i T θ(AjBkB′l). (4.3)
4.2.3 OBSERVED DATA
The observed data from a two-stage design (described in Figure 7) can be characterized as
a set of n independent vectors
{Vi, Xji, Li, Ri, RiZ1i, (1−Ri)Z ′1i, (tim, Yim),m = 1, 2, . . . ,M ; } , i = 1, 2, . . . , n,
where n is the total number of subjects in the sample; Vi is the baseline characteristics as
defined previously; Xji is the initial treatment indicator, Xji=1 when the i
th subject was
randomized to Aj, 0 otherwise; Li is the vector of covariates observed during the initial stage,
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Figure 7: Structure of observed data in a typical two-stage design
Z1i and Z
′
1i are the second-stage treatment indicators for B1 and B
′
1, respectively, i.e., Z1i=1
if the ithsubject received B1, and Z1i=0 otherwise. Similarly, Z
′
1i=1 if the i
th subject received
B′1, 0 otherwise; Yim is the outcome observed at time tim for the subject i, m = 1, 2, . . . ,M .
Let us define Z2i = 1−Z1i and Z ′2i = 1−Z ′1i so that Z2i and Z ′2i respectively represents the
indicators for B2 and B
′
2 respectively.
4.2.4 ASSUMPTIONS
As a first step toward estimation of the regime-specific parameters, counterfactual quantities
defined in section 4.2.1 will be expressed in terms of observed data. We make the consistency
assumption [29] that relates observed outcomes to the counterfactuals based on the actual
treatment received by the individuals. Namely,
Ri =
2∑
j=1
XjiRi(Aj), (4.4)
Li =
2∑
j=1
XjiLi(Aj), (4.5)
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and
Yim =
2∑
j=1
[
Xji
{
Ri
2∑
k=1
ZkiYim(AjBk) + (1−Ri)
2∑
l=1
Z ′liYim(AjB
′
l)
}]
. (4.6)
The consistency assumption implies that the potential outcome of a certain sequence of
treatment will remain unchanged regardless of the treatment assignment mechanism. In
addition, for consistent estimation of the treatment regime effects, we assume that actual
treatments received at different stages are independent of counterfactuals, conditional on
observed covariate history. Equivalently,
Pr(Xji = 1|Vi, Yim(AjBk), Yim(AjB′l), j, k, l = 1, 2) = Pr(Xji = 1|Vi), j = 1, 2, (4.7)
Pr(Zki = 1|Xji, Ri = 1, Vi, Li, Yim(AjBk), Yim(AjB′l), k, l = 1, 2)
= Pr(Zki = 1|Xji, Ri = 1, Vi, Li), j = 1, 2, (4.8)
and Pr(Z ′li = 1|Xji, Ri = 0, Vi, Li, Yim(AjBk), Yim(AjB′l), k, l = 1, 2)
= Pr(Z ′li = 1|Xji, Ri = 0, Vi, Li), j = 1, 2. (4.9)
This assumption is frequently referred to as ”No unmeasured confounder” [30] assump-
tion. In the case of the REVAMP study design, (4.8) and (4.9) are automatically satisfied,
since the second stage treatment is assigned through randomization. In addition, due to ran-
domization these latter probabilities do not depend on the covariates except for the response
status. Therefore, for simplicity, we will denote the probabilities in (4.8) and (4.9) by piAjBk
and piAjB′l respectively.
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4.3 ESTIMATION
As noted in the previous section, for fixed j, k, and l, the response for the regime AjBkB
′
l,
namely, Yim(AjBkB
′
l) is not observed for all patients. Therefore, the estimation proce-
dure would be carried out via group-specific sub-models. Specifically, all the individu-
als in the sample could be identified as belonging to one of the 8 subgroups, namely,
AjBk, AjB
′
l, j, k, l = 1, 2, where the subgroup AjBk refers to those who were treated with the
sequence of treatments Aj followed by Bk, and similarly for AjB
′
l. First we will express the
regime-specific parameters in terms of the group-specific parameters. We set the following
sub-models for group-specific responses Yim(AjBk) and Yim(AjB
′
l):
E [Yim(AjBk)|Vi, Li(Aj), tim] = V Ti α(AjBk) + LTi γ(AjBk) + β(AjBk)tim, (4.10)
and
E [Yim(AjB
′
l)|Vi, Li(Aj), tim] = V Ti α(AjB′l) + LTi γ(AjB′l) + β(AjB′l)tim. (4.11)
Or, equivalently,
E [Yim(AjBk)|V ∗i ] = V ∗i T θ(AjBk), (4.12)
and
E [Yim(AjB
′
l)|V ∗i ] = V ∗i T θ(AjB′l), (4.13)
where similar to the regime-specific notations for parameters, we defined group-specific pa-
rameters θ(AjBk) = {α(AjBk), γ(AjBk), β(AjBk)}T and θ(AjB′l) =
{α(AjB′l), γ(AjB′l), β(AjB′l)}T , j, k, l = 1, 2. We note that models (4.12) and (4.13) could
be fitted by using the data from patients who were treated using the respective sequences of
treatments. Thus, if we can express the regime specific parameters θ(AjBkB
′
l) in terms of
group-specific parameters θ(AjBk) and θ(AjB
′
l), then we will be able to estimate them with
ease. From Equation (4.1), we can write,
E [Yim(AjBkB
′
l)|V ∗i ] = E [Ri(Aj)Yim(AjBk)|V ∗i ] + E [{1−Ri(Aj)}Yim(AjB′l)|V ∗i ] .(4.14)
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If we further assume that conditional on V ∗i , Ri(Aj) and Yim(AjBk), and Ri(Aj), and
Yim(AjB
′
l) are statistically independent, then we obtain
E [Yim(AjBkB
′
l)|V ∗i ]
= E [Ri(Aj)|V ∗i ]E [Yim(AjBk)|V ∗i ] + E [1−Ri(Aj)|V ∗i ]E [Yim(AjB′l)|V ∗i ] . (4.15)
Let E(Ri(Aj)|V ∗i ) = pir(Aj) where pir(Aj) is the proportion of responders to the initial
treatment Aj, i.e., given the initial treatment assignment, probability of response does not
depend on V ∗i . Then (4.15) can be expressed as
E [Yim(AjBkB
′
l)|V ∗i ]
= pir(Aj)E [Yim(AjBk)|V ∗i ] + {1− pir(Aj)}E [Yim(AjB′l)|V ∗i ] . (4.16)
Under the model assumptions (4.10) and (4.11), equation (4.16) becomes
E [Yim(AjBkB
′
l)|V ∗i ] = V ∗Ti [pir(Aj)θ(AjBk) + {1− pir(Aj)}θ(AjB′l)] . (4.17)
By comparing (4.3) to (4.17), we can express the regime-specific parameter θ(AjBkB
′
l) as
the weighted average of treatment path specific parameters as follows
θ(AjBkB
′
l) = pir(Aj)θ(AjBk) + {1− pir(Aj)}θ(AjB′l). (4.18)
Since the outcome is measured repeatedly over time for the same individual, to account
for the correlation within individuals, one might use generalized estimating equations to
fit the group-specific models or introduce random effects into these models (mixed models).
Whatever way these models are fitted, once the group-specific parameters (θ(AjBk), θ(AjB
′
l))
are estimated along with the respective response rates, equation (4.18) could be used to
obtain the regime-specific parameter estimates from the group-specific parameter estimates.
Specifically,
θˆ(AjBkB
′
l) = pˆir(Aj)θˆ(AjBk) + {1− pˆir(Aj)}θˆ(AjB′l). (4.19)
For the purpose of our analysis we have used mixed models. We accommodate random
effects by adding the individual random component to the models (4.12) and (4.13). Let
HTi ηi(AjBk) and H
T
i ηi(AjB
′
l) be the random effect components for the subjects who follow a
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sequence of treatments AjBk and AjB
′
l, respectively, where Hi is the vector of random effects,
and ηi’s are random vectors of parameters for each subject having mean 0. For example,
if we choose the intercept and time as random effects, then Hi = [1, tim]
T , ηi(AjBk) =
[ηi0(AjBk), ηi1(AjBk)]
T , and ηi(AjB
′
l) = [ηi0(AjB
′
l), ηi1(AjB
′
l)]
T will represent the group-
specific parameters for random intercepts and slopes, respectively. In this case, the models
(4.12) and (4.13) are modified slightly as follows
E [Yim(AjBk)|V ∗i , ηi(AjBk)] = V ∗i T θ(AjBk) +HTi ηi(AjBk), (4.20)
and
E [Yim(AjB
′
l)|V ∗i , ηi(AjB′l)] = V ∗i T θ(AjB′l) +HTi ηi(AjB′l). (4.21)
We assume that ηi(AjBk) and ηi(AjB
′
l) are distributed as multivariate normal with
common mean 0 and variance-covariance matrices G(AjBk) and G(AjB
′
l) respectively. In
the following sections, we discuss two specific methods for estimating the fixed parameters
β(AjBkB
′
l), j, k, l = 1, 2.
4.3.1 PROPOSED METHODS
We propose two methods to estimate the effect of treatment regimes on the outcome over
time. In the first method, mixed model techniques are used to estimate β(AjBk) and
β(AjB
′
l) in the first step and then their weighted averages are used to derive the estimates
for β(AjBkB
′
l). We refer to this method as a two-step method. The second method uses
multiple imputation approach to reconstruct observations for subjects who did not follow
the regime of interest. This method involves one extra step of multiple imputation and
hence will be referred to as three-step method. Both two-step and three-step estimators are
described below in details.
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4.3.1.1 TWO-STEP METHOD
Step 1: Estimation of treatment effects for observed treatment sequences. For
each first stage treatment Aj, j = 1, 2, we obtain the empirical response rates
pˆir(Aj) =
∑n
i=1XjiRi∑n
i=1Xji
, j = 1, 2. (4.22)
Next we note that under the consistency and sequential randomization assumptions (4.4)-
(4.9), Yi(AjBk) = Yi when Xji = 1, Ri = 1, and Zki = 1 (and, similarly for other treatment
sequences). Therefore, for each of the eight observed sequences of treatments (AjBk, AjB
′
l),
j, k, l = 1, 2, we estimate β(AjBk), β(AjB
′
l), j, k, l = 1, 2 in this step using data from sub-
jects who received respective treatment sequence. For example, for j = k = 1, by fitting the
model (4.20) (with counterfactual Y ’s replaced with observed Y ’s) to the data from subjects
who followed the A1B1 treatment sequence, we obtain βˆ(A1B1). Any standard statistical
procedure, such as PROC MIXED in SAS [31] or the lme function in R [32] could be used
for this purpose. Note that the advantage of using such standard procedures is that the
estimated variance-covariance matrices for these parameter estimates are readily available
from the outputs generated by these routines. Also, model assumptions and structure of
the appropriate covariance matrix G could be thoroughly examined using these routines.
The residual check for normality and the covariance selection are described, for example, in
Brown and Prescott [17].
Step 2: Estimation of the overall treatment regime effects. The estimates for
each treatment regime effect βˆ(AjBkB
′
l) are constructed in this step. As described in (4.19),
the regime-specific parameter βˆ(AjBkB
′
l) are estimated as the weighted average
βˆ(AjBkB
′
l) = pˆir(Aj)βˆ(AjBk) + {1− pˆir(Aj)}βˆ(AjB′l).
As long as the estimators βˆ(AjBk) and βˆ(AjB
′
l) are unbiased, the above estimator is approx-
imately unbiased for the true parameter β(AjBkB
′
l). Approximate variance of βˆ(AjBkB
′
l) is
derived as follows
V ar{βˆ(AjBkB′l)} = E[V ar{βˆ(AjBkB′l)|pˆir(Aj)}] + V ar[E{βˆ(AjBkB′l)|pˆir(Aj)}],
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where
E[V ar{βˆ(AjBkB′l)|pˆir(Aj)}] = E[V ar(pˆir(Aj)βˆ(AjBk) + {1− pˆir(Aj)}βˆ(AjB′l)|pˆir(Aj))]
= E[pˆir(Aj)
2V ar(βˆ(AjBk)|pˆir(Aj))
+{1− pˆir(Aj)}2V ar(βˆ(AjB′l)|pˆir(Aj))]
= V ar(βˆ(AjBk))E(pˆir(Aj)
2) + V ar(βˆ(AjB
′
l))E({1− pˆir(Aj)}2)
= V ar(βˆ(AjBk))[V ar(pˆir(Aj)) + E(pˆir(Aj)
2)]
+V ar(βˆ(AjB
′
l))[V ar(1− pˆir(Aj)) + E({1− pˆir(Aj)}2)]
= V ar(βˆ(AjBk))[
pir(Aj){1− pir(Aj)}
nj
+ pir(Aj)
2]
+V ar(βˆ(AjB
′
l))[
pir(Aj)(1− pir(Aj))
nj
+ pir(Aj)
2]
where nj =
∑n
i=1Xji, and
V ar[E(βˆ(AjBkB
′
l)|pˆir(Aj))] = V ar[E{pˆir(Aj)βˆ(AjBk) + {1− pˆir(Aj)}βˆ(AjB′l)|pˆir(Aj)}]
= V ar[pˆir(Aj)β(AjBk) + {1− pˆir(Aj)}β(AjB′l)]
= {β(AjBk)− β(AjB′l)}2V ar(pˆir(Aj))
= {β(AjBk)− β(AjB′l)}2
pir(Aj)(1− pir(Aj))
nj
.
Thus,
V ar{βˆ(AjBkB′l)} = V ar(βˆ(AjBk))[
pir(Aj){1− pir(Aj)}
nj
+ pir(Aj)
2]
+V ar(βˆ(AjB
′
l))[
pir(Aj){1− pir(Aj)}
nj
+ pir(Aj)
2]
+{β(AjBk)− β(AjB′l)}2
pir(Aj){1− pir(Aj)}
nj
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4.3.2 THREE-STEP METHOD
Step 1: Estimation of treatment effect for each treatment sequence. For simplicity,
consider the regime A1B1B
′
1. We first use Step 1 of the two-step method to obtain pˆiR(A1),
βˆ(A1B1), βˆ(A1B2), βˆ(A1B
′
1), and βˆ(A1B
′
2).
Step 2: Multiple imputation. Since a subject is randomized to one of the second-stage
treatments, the subject’s outcome for the other second-stage treatment is unobserved. For
example, if a subject responds to A1 and receives B1, then this subject is not able to receive
B2 at the same time. Therefore, the outcome based on the B2 are unobserved for this subject.
We will treat this as a missing-data problem, and impute the outcomes as if the subject
also received the other second-stage treatment at the same time. Since a single imputation
method generates smaller standard errors in general [19], multiple imputation method is
applied to reconstruct the potential outcome data for these patients (who received A1B2)
based on their covariate history and the information borrowed from subjects who received
A1B1. First we estimate the fixed parameters θ(A1B1) and variance-covariance matrix G
for the corresponding random effects by fitting the model (4.20) to subjects who received
A1B1 sequence. Then for each individual receiving the sequence A1B2, we use I random
draws from the random effect distribution and combine it with the parameter estimate and
covariate information of the A1B2 subjects to impute their potential outcomes Y (A1B1). At
the end of the imputation process, there will be I newly created datasets, containing the
observed outcomes for the A1B1 subjects, and imputed outcomes for the A1B2 subjects.
Step 3: Estimation of the overall treatment regime effects. Because of the imputed
potential outcomes in Step 2, every subject is now consistent with every regime. Therefore,
we can directly estimate the overall treatment regime effects by fitting model (4.2) to these
I datasets to obtain βˆ(`)(A1B1B
′
1), ` = 1, 2, . . . , I, and the imputed estimator for β(A1B1B
′
1)
is defined as
βˆIMP (A1B1B
′
1) =
1
I
I∑
`=1
βˆ(`)(A1B1B
′
1).
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Since we adapted the multiple imputations in Step 2, we need to account for both within
and between subjects variabilities. Following the formula given in Little [19], the variance
of the imputed estimator can be estimated by
V ar
{
βˆIMP (A1B1B
′
1)
}
=
1
I
I∑
`=1
V ar
{
βˆ(`)(A1B1B
′
1)
}
+
I + 1
I(I − 1)
I∑
`=1
{
βˆ(`)(A1B1B
′
1)− βˆIMP (A1B1B′1)
}2
.(4.23)
The treatment effects for the other treatment sequences are estimated in a similar manner.
The variance of this estimator is expected to be larger than the variance of the two-step
estimator as multiple imputations introduces further variability into the model.
than the variance of the two-step estimator as multiple imputations introduces further vari-
ability into the model.
4.4 HYPOTHESIS TESTING
Finding the best treatment regime in the two-stage randomized designs is equivalent to
simultaneously testing whether one treatment regime is significantly superior to the others.
Specifically, testing the following null hypothesis is our primary interest:
H0 : β(A1B1B
′
1) = β(A1B1B
′
2) = β(A1B2B
′
1) = β(A1B2B
′
2)
Since this null hypothesis is equivalent to testing three pair-wise comparisons between
β(A1B1B
′
1) and β(A1B1B
′
2), β(A1B1B
′
1) and β(A1B2B
′
1), and β(A1B1B
′
1) and β(A1B2B
′
2),
the null hypothesis can also be expressed as
H0 : A
Tβ = 0 (4.24)
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where,
β =

β(A1B1B
′
1)
β(A1B1B
′
2)
β(A1B2B
′
1)
β(A1B2B
′
2)
 ,
and
AT =

1 -1 0 0
1 0 -1 0
1 0 0 -1
 .
The test statistics is constructed as the Wald statistic
χ2 = βˆTA{ATCov(βˆ)A}−1AT βˆ, (4.25)
where, βˆ is the vector of parameter estimates corresponding to β and Cov(βˆ) is the estimated
variance-covariance matrix of βˆ. In the previous section, we had derived the formula for
the variance of βˆ(AjBkB
′
l), which can be estimated by substituting unbiased estimates of
the appropriate quantities. The covariance between βˆ(A1B1B
′
1) and βˆ(A1B2B
′
2), as well as
βˆ(A1B2B
′
1) and βˆ(A1B1B
′
2) are set to zero since these treatment regimes are independent as
they do not share any common second stage treatments. To obtain the covariances between
other regime-specific coefficients, we use a method similar to the multivariate delta method
[33] based on the Taylor series expansion of the estimator itself. The parameter β(AjBkB
′
l)
is treated as the function of the three unknown parameters (i.e. pir(Aj), β(AjBk), and
β(AjB
′
l)), so that using Taylors series expansion, we obtain
βˆ(AjBkB
′
l)
= pˆir(Aj)βˆ(AjBk) + {1− pˆir(Aj)}βˆ(AjB′l)
≈ β(AjBkB′l) + {β(AjBk)− β(AjB′l)}{pˆir(Aj)− pir(Aj)}+ {βˆ(AjBk)− β(AjBk)}pˆir(Aj)
+{βˆ(AjB′l)− β(AjB′l)}{1− pir(Aj)}.
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Then, the covariance between βˆ(A1B1B
′
1) and βˆ(A1B1B
′
2) is approximated by
cov[βˆ(A1B1B
′
1)βˆ(A1B1B
′
2)]
= E[{βˆ(A1B1B′1)− β(A1B1B′1)}{βˆ(A1B1B′2)− βˆ(A1B1B′2)}]
≈ E[({(β(A1B1)− β(A1B′1)}{pˆi(A1)− pir(A1)}
+{βˆ(A1B1)− β(A1B1)}pˆir(A1) + {βˆ(A1B′1)− β(A1B′1)}{1− pir(A1)}),
{(β(A1B1)− β(A1B′2)}{pˆir(A1)− pir(A1)}+ {βˆ(A1B1)− β(A1B1)}pˆir(A1)
+{βˆ(A1B′2)− β(A1B′2)}{1− pir(A1)})]
= E[{β(A1B1)− β(A1B′1)}{β(A1B1)− β(A1B′2)}{pˆir(A1)− pir(A1)}2
= E[{β(A1B1)− β(A1B′1)}{β(A1B1)− β(A1B′2)}{pˆir(A1)− pir(A1)}2]
= {β(A1B1)− β(A1B′1)}{β(A1B1)− β(A1B′2)}V ar(pˆir(A1))
= {β(A1B1)− β(A1B′1)}{β(A1B1)− β(A1B′2)}
[
pir(A1){1− pir(A1)}
n1
]
.
The covariance then can be estimated by replacing the parameters with the corresponding
estimates.
Under the null hypothesis, the Wald statistic (4.25) is compared to the critical values
of a χ23 distribution. Other linear combinations of regime-specific treatment effects may be
tested in a similar manner.
4.5 SIMULATION STUDY
In order to examine the properties of the proposed estimators, we have conducted several
simulation studies. We generated data by simulating a two-stage randomized study as shown
in Figure 6. The number of follow-up visits during the second stage was set to four. For
simplicity, we only generated data for the subjects with A1 treatment, and therefore, we will
have only four treatment regimes, namely, A1B1B
′
1, A1B1B
′
2, A1B2B
′
1, and A1B2B
′
2.
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For individual i, the response status Ri is generated from a Bernoulli distribution with
mean pir = 0.5. Given the response status, the second-stage treatment indicators Z1i and Z
′
1i
were generated respectively for responders and non-responders from Bernoulli distributions
with piA1B1 = 0.5 and piA1B′1 = 0.5. The covariate, age, is randomly drawn from a normal
distribution with mean 30, with standard deviation of 5. The initial stage outcome y(1)
depends on Ri and it was generated from a normal distribution with a mean of 20 for the
responders and 30 for the non-responders. The variance was set to 2 for both responders
and non-responders. For the repeatedly measured outcomes for the subjects receiving AjBk,
we generated the data from the following model
Yim(AjBk) = {η0i + β0(AjBk)}+ {η1i + β1(AjBk)}tim + α(AjBk)agei + γ(AjBk)y(1)i + im,
where (η0i, η1i)
T ∼ N(0, G(AjBk)), im ∼ N(0, σ2e), and independently of η0i and η1i. We set
G(AjBk) as
G(AjBk) =
 σ0 ρ√σ0σ1
ρ
√
σ0σ1 σ1
 .
Similarly, the true outcome for the sequence of treatments AjB
′
l was generated using
Yim(AjB
′
l) = {η′0i + β0(AjB′l)}+ {η′1i + β1(AjB′l)}tim + α(AjB′l)agei + γ(AjB′l)y(1)i + ′im,
where (η′0i, η
′
1i)
T ∼ N(0, G(AjB′l)), and ′im ∼ N(0, σ′2e ). For our simulations, we set G(AjBk)
= G(AjB
′
l) and σ
2
e = σ
′2
e . Thus our models have intercept and time as both fixed and random
effects.
In simulation scenario 1, we assumed that there were clear treatment differences among
four treatment sequences, while in simulation scenario 2, there was no treatment differences.
In scenario 1, we choose β0(A1B1)=β0(A1B2)=20, β1(A1B1)=-2.5, β1(A1B2)=-0.1, β0(A1B
′
1)
= β0(A1B
′
2) = 30, β1(A1B
′
1) = -2.0 and β1(A1B
′
2) = -0.5, leading to β(A1B1B
′
1) = -2.25,
β(A1B1B
′
2) = -1.50, β(A1B2B
′
1) = -1.05, and β(A1B2B
′
2) = -0.30. In scenario 2, we changed
the parameters to β0(A1B1) = β0(A1B2) = 20, β0(A1B
′
1) = β0(A1B
′
2) = 30, and β1(A1B1)
= β1(A1B2) =β1(A1B
′
1) = β1(A1B
′
2) = 0, leading to no treatment effect for all regimes. The
parameters for the variance-covariance matrix G were set to σ0 = 0.35, σ1 = 0.25, and ρ =
0.001. For the variance of im, σ
2
e was set to 2. The sequence-specific age effects were set
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to α(A1B1) = 0.1, α(A1B2) = 0.2, α(A1B
′
1) = 0.15, and α(A1B
′
2) = 0.25. Finally, we chose
the effect of initial stage outcome as γ(A1B1) = γ(A1B
′
1) = -0.2, and γ(A1B2) = γ(A1B
′
2)
= -0.25.
Since it is unrealistic to assume that everyone completes the study, in addition to creating
two different scenarios for the treatment regime effect, the proposed methods were tested in
different missing data situations [19]: (1) no missing data, (2) missing completely at random
(MCAR), and (3) missing at random (MAR). For its simplicity, we selected a monotone
missing pattern for both MCAR and MAR situations. Selecting the monotone missing
pattern means that we assume that once a subject misses a visit, all subsequent visits are
missed as well. For the MCAR situation, at first, 30% and 60% of subjects were randomly
selected to have some outcome data missing. Of these, 50% were randomly selected to
have missing Yi4, and the remaining 50% were to have missing Yi3 and Yi4. For the MAR
situation, we also generated 30% and 60% missing data. However, in this case, the rate of
missing data depended on the treatment sequences. When 30% of data are missing, 2.5%
among the subjects with treatment sequences A1B1 or A1B2, 10% among the subjects with
A1B
′
1, and 15% among the A1B
′
2 subjects have some missing data. The percentages were
doubled for the 60% missing situation. Similar to the MCAR situation, among those who
had missing data, 50% of them were missing Yi4, and the other 50% have missing Yi3 and
Yi4. In both scenarios and all missing situations, 500 Monte-Carlo datasets were generated
with two different sample sizes of 500 and 1000. Only for the complete data situation, we
generated additional datasets with a sample size of 200.
For each simulated dataset, β(AjBkB
′
l), j, k, l = 1, 2 and their standard errors were esti-
mated using the methods described in Section 4.3. Results are presented using Monte Carlo
means, standard errors, and coverage probabilities of 95% CIs. The simulation results are
summarized in Tables 4 to 10.
Table 4 shows the results of scenario 1 when there was no missing data. For all sample
sizes, the estimates from both two-step and three-step methods were very close to the true
values with negligible biases (0.00-0.04). The variance estimators for two-stage method were
consistent as seen by the agreement between the average estimated standard error and the
MCSE. However, the variance estimator for the three-step method was larger than the MCSE
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Table 4: Simulation result for two- and three-step methods with no missing
data. Monte Carlo mean, Monte Carlo standard error, standard error, and coverage rate
(based on 95% C.I.) for all treatment regimes when the treatment regimes differ
Two-step Method Three-step Method
SampleTreatment True MC Mean SE Coverage MC Mean SE Coverage
Size Regime Param. (MCSE) Rate(%) (MCSE) Rate(%)
200 A1B1B
′
1 -2.25 -2.24(0.099) 0.096 93.0 -2.28(0.099) 0.097 93.4
A1B1B
′
2 -1.50 -1.50(0.119) 0.102 90.4 -1.54(0.120) 0.135 96.0
A1B2B
′
1 -1.05 -1.05(0.119) 0.101 91.2 -1.09(0.119) 0.108 91.0
A1B2B
′
2 -0.30 -0.30(0.095) 0.096 95.6 -0.34(0.096) 0.094 92.4
500 A1B1B
′
1 -2.25 -2.25(0.062) 0.060 95.2 -2.26(0.062) 0.059 94.0
A1B1B
′
2 -1.50 -1.50(0.078) 0.064 90.2 -1.51(0.078) 0.079 95.6
A1B2B
′
1 -1.05 -1.05(0.073) 0.064 91.6 -1.06(0.073) 0.065 91.6
A1B2B
′
2 -0.30 -0.30(0.062) 0.060 94.6 -0.32(0.062) 0.057 92.2
perhaps due to the multiple imputations. For the two-step method, the coverage rate ranged
between 90.2% and 95.6% while the range for the three-step method was between 91.0%
and 96.0%. The results of scenario 2 when there is no missing data are reported in Table
6. Again the estimates were approximately unbiased, and the coverage rates for the two
methods were similar. For both methods, increase in sample size from 200 to 500 did not
affect the properties of the estimators.
Tables 7 and 8 summarize the results of scenarios 1 and 2 respectively when the miss-
ing data are completely at random. The estimates for both methods were approximately
unbiased, and as expected, the percentage of missing data did not affect the estimates. Com-
pared to the two-step method, the three-step method had slightly larger bias, probably due
to the additional variability introduced through multiple imputation. The coverage rates for
the three-step method were generally higher (93.6%-98.6%) than the ones for the two-step
method (90.6%-95.6%) since the variance estimates were larger than the MC variances. Since
the estimates from the mixed models are expected to be unbiased when the data are missing
completely at random, the results are not unexpected.
Tables 9 and 10 report the results of scenario 1 and 2 when the data are missing at
random. The results were very similar to those from the MCAR situation. The estimates
were approximately unbiased even when 60% of the data had at least one missing assessment.
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Table 5: Simulation result for two- and three-step methods with no missing
data. Monte Carlo mean, Monte Carlo standard error, standard error, and coverage rate
(based on 95% C.I.) for all treatment regimes when there were no effects of treatment regime
Two-step Method Three-step Method
Sample Treatment MC Mean MCSE Coverage MC Mean MCSE Coverage
Size Regime (SE) Rate(%) (SE) Rate(%)
200 A1B1B
′
1 0.00(0.095) 0.096 95.0 -0.05(0.095) 0.095 92.0
A1B1B
′
2 -0.01(0.095) 0.096 95.2 -0.05(0.096) 0.098 92.6
A1B2B
′
1 0.00(0.095) 0.095 94.4 -0.04(0.094) 0.091 91.2
A1B2B
′
2 -0.01(0.094) 0.095 95.0 -0.05(0.093) 0.094 92.8
500 A1B1B
′
1 0.00(0.063) 0.060 94.8 -0.01(0.063) 0.057 92.6
A1B1B
′
2 0.01(0.058) 0.060 96.4 -0.01(0.058) 0.060 95.6
A1B2B
′
1 0.00(0.063) 0.060 93.8 -0.01(0.063) 0.055 90.2
A1B2B
′
2 0.00(0.059) 0.060 96.6 -0.01(0.059) 0.057 94.4
4.6 APPLICATION TO REVAMP DATA
The proposed methods were applied to a dataset from the REVAMP study, that motivated
this research. In the REVAMP study (see section 1 for details), the initial treatment was
not randomly assigned. We compare the treatment regimes that shares the same initial
treatment. This will allow us, for example, to answer the question of which treatment
regime results in the greatest reduction of depression scores over time, given the subject
received SERT as an initial treatment. The REVAMP study provides four initial treatment
options. However since the number of subjects who received BUP-SR and VLF-XR were
small, we focus on estimating the effect of treatment regimes for those who received SERT
only. Figure 8 illustrates the number of patients with SERT including actual treatment
sequences. A total of 618 subjects received SERT, and there were three possible regimes
for the subjects with SERT: (1) Treat with SERT and if responded, continue to treat with
SERT, otherwise change or add medication (n=186), (2) Treat with SERT and if responded,
continue to treat with SERT, otherwise treat with the CBASP (n=250), and (3) Treat with
SERT and if responded, continue to treat with SERT, otherwise treat with the SP (n=259).
Figure 9 shows trajectories of first- and second-stage outcomes for six selected subjects.
The vertical lines indicate the end of the initial stage. Subjects 1 and 2 show a trend of
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Table 6: Simulation result for two- and three-step methods with no missing
data. Monte Carlo mean, Monte Carlo standard error, standard error, and coverage rate
(based on 95% C.I.) for all treatment regimes when there were no effects of treatment regime
Two-step Method Three-step Method
Sample Treatment MC Mean MCSE Coverage MC Mean MCSE Coverage
Size Regime (SE) Rate(%) (SE) Rate(%)
200 A1B1B
′
1 0.00(0.095) 0.096 95.0 -0.05(0.095) 0.095 92.0
A1B1B
′
2 -0.01(0.095) 0.096 95.2 -0.05(0.096) 0.098 92.6
A1B2B
′
1 0.00(0.095) 0.095 94.4 -0.04(0.094) 0.091 91.2
A1B2B
′
2 -0.01(0.094) 0.095 95.0 -0.05(0.093) 0.094 92.8
500 A1B1B
′
1 0.00(0.063) 0.060 94.8 -0.01(0.063) 0.057 92.6
A1B1B
′
2 0.01(0.058) 0.060 96.4 -0.01(0.058) 0.060 95.6
A1B2B
′
1 0.00(0.063) 0.060 93.8 -0.01(0.063) 0.055 90.2
A1B2B
′
2 0.00(0.059) 0.060 96.6 -0.01(0.059) 0.057 94.4
Table 7: Simulation result for two- and three-step methods with 30% and 60%
MCAR data. Monte Carlo mean, Monte Carlo standard error, standard error, and cov-
erage rate (based on 95% C.I.) for all treatment regimes when the treatment regimes differ
Two-step Method Three-step Method
SampleMissingTreatment True MC Mean MC Coverage MC Mean MC Coverage
Size Rate Regime Param. (SE) SE Rate(%) (SE) SE Rate(%)
500 30% A1B1B
′
1 -2.25 -2.25(0.066) 0.067 95.4 -2.27(0.066) 0.072 96.4
A1B1B
′
2 -1.50 -1.50(0.081) 0.070 90.6 -1.52(0.081) 0.091 96.8
A1B2B
′
1 -1.05 -1.05(0.077) 0.070 94.2 -1.07(0.078) 0.076 93.8
A1B2B
′
2 -0.30 -0.30(0.068) 0.066 95.2 -0.32(0.069) 0.069 93.6
60% A1B1B
′
1 -2.25 -2.25(0.076) 0.075 94.0 -2.28(0.077) 0.100 97.2
A1B1B
′
2 -1.50 -1.50(0.092) 0.078 90.2 -1.54(0.092) 0.120 98.2
A1B2B
′
1 -1.05 -1.05(0.087) 0.078 93.0 -1.08(0.088) 0.096 97.0
A1B2B
′
2 -0.30 -0.30(0.074) 0.074 94.6 -0.34(0.075) 0.094 97.4
1000 30% A1B1B
′
1 -2.25 -2.25(0.046) 0.046 95.4 -2.26(0.054) 0.069 98.2
A1B1B
′
2 -1.50 -1.50(0.056) 0.049 90.6 -1.51(0.065) 0.085 98.6
A1B2B
′
1 -1.05 -1.05(0.055) 0.049 91.2 -1.06(0.064) 0.064 95.0
A1B2B
′
2 -0.30 -0.30(0.048) 0.046 94.0 -0.31(0.054) 0.064 97.0
60% A1B1B
′
1 -2.25 -2.25(0.054) 0.053 95.6 -2.26(0.054) 0.069 98.2
A1B1B
′
2 -1.50 -1.50(0.064) 0.055 91.6 -1.51(0.065) 0.085 98.6
A1B2B
′
1 -1.05 -1.05(0.062) 0.055 92.2 -1.06(0.064) 0.064 95.0
A1B2B
′
2 -0.30 -0.30(0.053) 0.053 93.2 -0.31(0.054) 0.064 97.0
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Table 8: Simulation result for two- and three-step methods with 30% and 60%
MCAR data. Monte Carlo mean, Monte Carlo standard error, standard error, and cover-
age rate (based on 95% C.I.) for all treatment regimes when there were no effects of treatment
regime
Two-step Method Three-step Method
SampleMissingTreatment MC Mean MC Coverage MC Mean MC Coverage
Size Rate Regime (SE) SE Rate(%) (SE) SE Rate(%)
500 30% A1B1B
′
1 0.00(0.070) 0.066 93.4 -0.02(0.069) 0.070 93.6
A1B1B
′
2 0.01(0.064) 0.066 97.0 -0.02(0.065) 0.073 97.0
A1B2B
′
1 0.00(0.068) 0.066 94.2 -0.02(0.068) 0.068 93.6
A1B2B
′
2 0.00(0.063) 0.066 95.0 -0.02(0.068) 0.070 96.0
60% A1B1B
′
1 0.00(0.075) 0.075 94.2 -0.03(0.075) 0.096 97.8
A1B1B
′
2 0.00(0.072) 0.075 95.4 -0.03(0.072) 0.100 99.0
A1B2B
′
1 0.00(0.078) 0.075 94.0 -0.04(0.078) 0.093 96.2
A1B2B
′
2 0.00(0.075) 0.075 94.2 -0.04(0.075) 0.096 98.0
1000 30% A1B1B
′
1 0.00(0.047) 0.046 95.6 0.00(0.047) 0.047 95.4
A1B1B
′
2 0.00(0.046) 0.046 95.4 0.00(0.046) 0.049 96.6
A1B2B
′
1 0.00(0.046) 0.046 96.0 0.00(0.046) 0.046 95.6
A1B2B
′
2 0.00(0.048) 0.046 94.2 0.00(0.048) 0.047 95.0
60% A1B1B
′
1 0.00(0.054) 0.053 94.6 -0.01(0.055) 0.066 98.4
A1B1B
′
2 0.00(0.053) 0.053 95.6 -0.01(0.053) 0.069 99.0
A1B2B
′
1 0.00(0.055) 0.053 94.8 -0.01(0.055) 0.063 97.8
A1B2B
′
2 0.00(0.052) 0.053 94.6 -0.01(0.053) 0.066 98.4
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Table 9: Simulation result for two- and three-step methods with 30% and 60%
MAR data. Monte Carlo mean, Monte Carlo standard error, standard error, and coverage
rate (based on 95% C.I.) for all treatment regimes when the treatment regimes differ
Two-step Method Three-step Method
SampleMissingTreatment True MC Mean MC Coverage MC Mean MC Coverage
Size Rate Regime Param. (SE) SE Rate(%) (SE) SE Rate(%)
500 30% A1B1B
′
1 -2.25 -2.25(0.069) 0.066 94.0 -2.27(0.069) 0.070 93.4
A1B1B
′
2 -1.50 -1.50(0.084) 0.071 90.6 -1.50(0.084) 0.094 96.4
A1B2B
′
1 -1.05 -1.05(0.078) 0.070 91.0 -1.08(0.079) 0.076 94.0
A1B2B
′
2 -0.30 -0.30(0.069) 0.068 96.0 -0.32(0.069) 0.074 96.8
60% A1B1B
′
1 -2.25 -2.25(0.069) 0.071 95.4 -2.28(0.070) 0.086 97.0
A1B1B
′
2 -1.50 -1.50(0.088) 0.078 91.0 -1.56(0.089) 0.119 96.4
A1B2B
′
1 -1.05 -1.05(0.087) 0.078 91.4 -1.10(0.089) 0.098 93.0
A1B2B
′
2 -0.30 -0.30(0.083) 0.079 93.0 -0.34(0.084) 0.108 98.0
1000 30% A1B1B
′
1 -2.25 -2.25(0.047) 0.046 95.2 -2.25(0.043) 0.041 92.6
A1B1B
′
2 -1.50 -1.50(0.055) 0.050 92.4 -1.50(0.053) 0.055 96.8
A1B2B
′
1 -1.05 -1.05(0.056) 0.049 91.6 -1.05(0.053) 0.045 90.4
A1B2B
′
2 -0.30 -0.30(0.047) 0.048 94.6 -0.30(0.044) 0.040 91.6
60% A1B1B
′
1 -2.25 -2.25(0.054) 0.053 95.6 -2.25(0.043) 0.041 92.6
A1B1B
′
2 -1.50 -1.50(0.064) 0.055 91.6 -1.50(0.053) 0.055 96.8
A1B2B
′
1 -1.05 -1.05(0.062) 0.055 92.2 -1.05(0.053) 0.045 90.4
A1B2B
′
2 -0.30 -0.30(0.053) 0.053 93.2 -0.30(0.044) 0.040 91.6
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Table 10: Simulation result for two- and three-step methods with 30% and 60%
MAR data. Monte Carlo mean, Monte Carlo standard error, standard error, and coverage
rate (based on 95% C.I.) for all treatment regimes when there were no effects of treatment
regime
Two-step Method Three-step Method
SampleMissingTreatment MC Mean MC Coverage MC Mean MC Coverage
Size Rate Regime (SE) SE Rate(%) (SE) SE Rate(%)
500 30% A1B1B
′
1 0.00(0.067) 0.065 95.0 -0.02(0.068) 0.068 93.8
A1B1B
′
2 0.01(0.065) 0.067 97.0 -0.01(0.066) 0.075 97.4
A1B2B
′
1 0.00(0.070) 0.067 92.8 -0.02(0.070) 0.069 92.4
A1B2B
′
2 0.00(0.065) 0.068 95.8 -0.02(0.066) 0.076 96.4
60% A1B1B
′
1 0.01(0.072) 0.071 94.6 -0.02(0.072) 0.083 97.6
A1B1B
′
2 0.01(0.074) 0.075 95.8 -0.01(0.075) 0.098 98.8
A1B2B
′
1 0.00(0.079) 0.075 95.0 -0.03(0.079) 0.094 97.6
A1B2B
′
2 0.00(0.077) 0.079 95.2 -0.03(0.077) 0.111 99.4
1000 30% A1B1B
′
1 0.00(0.046) 0.046 95.2 0.00(0.047) 0.046 94.8
A1B1B
′
2 0.00(0.048) 0.047 94.8 0.00(0.048) 0.052 96.8
A1B2B
′
1 0.00(0.047) 0.047 95.2 0.00(0.047) 0.046 94.6
A1B2B
′
2 0.00(0.050) 0.048 93.6 0.00(0.050) 0.051 95.0
60% A1B1B
′
1 0.00(0.050) 0.050 95.2 0.00(0.047) 0.046 94.8
A1B1B
′
2 0.00(0.053) 0.053 94.8 0.00(0.048) 0.052 96.8
A1B2B
′
1 0.00(0.053) 0.053 94.6 0.00(0.047) 0.046 94.6
A1B2B
′
2 0.00(0.056) 0.056 95.8 0.00(0.050) 0.051 95.0
Figure 8: Patients receiving SERT as initial treatments in REVAMP design
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Figure 9: Outcome trend for responders, partial-responders, and non-responders. The
vertical lines indicate the end of the initial stage
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outcomes for the responders. Since the outcome was measured by HRSD24, lower scores
indicate that subjects are recovering from the MDD. For Subject 1, the initial treatment
was effective so that the HRSD24 score was reduced significantly by the second visit, and
the subject continued with the same treatment at the follow-up stage. For subject 2, the
initial treatment also worked well, and this subject decided not to stay in the study for the
follow-up stage. The outcome trend for the partial-responders is illustrated by Subjects 3
and 4. For these subjects, the initial treatment was not as effective as the first two subjects.
They moved to the second-stage and continued to be treated with one of the second-stage
treatments. Subjects 5 and 6 are non-responders. Their scores over time remained high, and
at the end of the initial stage, they were randomized to one of the second stage treatments.
We analyzed the HRSD24 scores in the second stage using the methods described in
previous sections. Since we assume that each subject join the study with varying medication
history, and the effect of the same treatment may vary across subjects, we selected to fit
random coefficient models with random intercept and slope. For the two-step method, in
Step 1, we fit the models as in (4.20) and (4.21). We decided to include the baseline age
and the HRSD24 score at the end of initial stage (y
(1)) as covariates so that V Ti =[1i, Agei],
LTi =y
(1)
i , tim is the week (treated continuous), at which m
th measurement is taken, and
HTi =[1i, tim] is the design matrix for random intercept and slope. Specifically, a model for
those who received MC as a second-stage treatment is as follows
Yim(MC) = α1(MC) + α2(MC)Agei + γ3(MC)y
(1)
i + β1(MC)tim + η1i(MC)
+η2i(MC)tim + im. (4.26)
Similar models were used for the other second-stage treatments CBASP/MC and SP/MC.
In Step 2, as in (4.19), three overall effects for the three treatment regimes β(SERT-MC),
β(SERT-CBASP/MC), and β(SERT-SP/MC) were estimated. We also used the three-step
methods to estimate theses parameters.
For both methods, we have tested if there were any differences in treatment effects among
treatment regimes within each initial treatment. We used a Wald Chi-square test with 2
degree of freedom. The results of the data analysis are summarized in Table 11.
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Table 11: REVAMP data analysis result
Initial Trt Method Regime βtime(SE) Test Statistic P-value
SERT Two-step SERT-MC -0.409 (0.11) 0.172 0.9172
SERT-CBASP/MC -0.435 (0.08)
SERT-SP/MC -0.389 (0.08)
Three-step SERT-MC -0.359 (0.09) 1.043 0.593
SERT-CBASP/MC -0.478 (0.09)
SERT-SP/MC -0.449 (0.08)
Among the SERT regimes, both methods showed that the SERT-CBASP/MC regime
seems to be the most effective, followed by the SERT-SP/MC and the SERT-MC regimes.
However, the Wald Chi-square test showed that the three regimes were not significantly dif-
ferent from each other.
4.7 DISCUSSION
We proposed two methods (we referred them as two- and three-step methods) to estimate
the effect of treatment regimes from a sequentially randomized two stage trial when data
are collected longitudinally. These methods took two different approaches. The two-step
method adapted mixed model techniques to estimate the observed treatment sequence effects,
and those estimates were combined to obtain the overall treatment regime effect by taking
their weighted averages. For the three-step method, a multiple imputation method was
used to impute outcomes for those who were not consistent with the regime of interest due
to randomization. After the imputation process, the treatment regime effect was directly
estimated by fitting a mixed model for each treatment regime. Both methods are simple to
apply since standard statistical packages can be used to implement them. Simulation results
showed that the estimates provide good coverage rates for 95% confident intervals. However,
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mixed models are sensitive to normality assumption [17] as well as a missing data [19]. To
account for the former, one can accomodate GEE-type peocedures in the methods described
here. We investigated the issue of missing data patterns in our simulations to show that
the methods proposed work well when the missing is (completely) at random. The issue of
missing not at random is addressed in Chpater 5.
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5.0 ASSESSING THE EFFECT OF TREATMENT REGIMES WHEN
LONGITUDINAL OUTCOME DATA ARE NOT MISSING AT RANDOM
5.1 INTRODUCTION
In longitudinal clinical trials, missing data are often unavoidable. In REVAMP study (de-
scribed in Chapter 4), 11% of subjects dropped out from the study during the first stage for
various reasons. Some subjects stopped participating in the study since they felt the treat-
ment was not effective, and some subjects simply moved to a different location. Examinig
the subjects’ dropout pattern is important since standard methods for analyzing repeatedly
measured outcomes, such as generalized estimating equations (GEE), have limitations such
that the data need to be missing completely at random (MCAR) or at least missing at ran-
dom (MAR). When data are not missing at random (NMAR), these methods are known to
produce biased results [17]. Therefore, different methods such as Pattern Mixture models
[20] or Selection models [21] need to be employed. In this chapter, we propose a method to
assess the effect of two-stage treatment strategies on longitudinally observed outcome data
when data are NMAR.
In Section 5.2, we first review three patterns of missing data and a standard method
for the analysis of NMAR data such as a random-coefficient pattern mixture model. The
proposed method is described in Section 5.3. The results from simulation studies are reported
in Section 5.4, followed by the discussion in Section 5.5.
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5.2 MISSING DATA REVIEW
5.2.1 THREE PATTERNS OF MISSING DATA
According to Rubin [18], there are three different types of missing data mechanism: (1) Miss-
ing Completely at Random (MACAR), (2) Missing at Random (MAR), and (3) Not Missing
at Random (NMAR). First let us define G as the missing data indicator vector, Y be the
outcome matrix which includes observed outcome Yobs and missing outcome Ymis, and φ is
the unknown parameter associated with missing data. MCAR and MAR can be expressed
as
1. MCAR: f(G|Y, φ) = f(G|φ) for all Y and φ
2. MAR: f(G|Y, φ) = f(G|Yobs, φ) for all Ymis and φ,
In words, if missing data do not depend on the outcomes, the data are classified as MCAR.
If missing data depends on Yobs and φ, the data are considered as MAR, and if the missing
data depend on Ymis, the data are NMAR.
The NMAR data in a longitudinal study occur when subjects drop out from the study
because of their health-related outcomes. For example, if a subject receive a treatment at
baseline and if it is not effective (i.e. the outcomes continuously showed that he/she was not
responding to the treatment), the subject might choose not to participate in the study any
further. This type of dropout needs to be distinguished from random dropouts.
5.2.2 RANDOM-COEFFICIENT PATTERN MIXTURE MODELS
When missing data are NMAR, standard methods for analyzing continuous outcome data
such as GEE or Mixed Models produce biased results [19]. For such data, the pattern mixture
models [20] and the selection models [21] are the two most common methods. Since the
pattern mixture models have an advantage that we do not have to specify the distribution of
missing patterns, in this chapter, we focus on this approach. Since we selected to use random-
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coefficient models in Section 5.3, we review random-coefficient pattern mixture models below.
The random-coefficient pattern mixture models can be fitted in three-steps: fit a random
coefficient model per stratified data, find the estimate for the parameter of interest, and fi-
nally combine the estimates by multiplying with the proportion of each missing data pattern.
This models can be expressed as a factorized likelihood. For ith subject where i = 1, ..n, let
Yi be the vector of continuous outcomes, Gi is the missing data indicator, Xi is the fixed
covariate design matrix, and βi is the coefficient of random effect. The joint likelihood of Yi,
Gi and βi can be factorized as follows
[Yi, Gi, βi|Xi] = [Yi|Xi, βi, Gi][βi|Xi, Gi][Gi|Xi], (5.1)
where [Yi|Xi, βi, Gi] models the repeated outcomes stratified by missing data pattern,
[βi|Xi, Gi] models the within-subject variation due to random effect, and [Gi|Xi] models the
proportion of subjects in each missing data pattern.
Little [20] introduces one special type of random-coefficient pattern mixture models. It
is called Random-effect-dependent drop-out model, and we assume that the missing pattern
depends only on Xi and βi. In this model, the joint likelihood is simplified to
[Yi, Gi, βi|Xi] = [Yi|βi][βi|Xi, Gi][Gi|Xi]. (5.2)
and each component of the joint likelihood assumed to have the following distributions
[Yi|βi] ∼ NM
(
1 ti1
...
...
1 tiM

 βi0
βi1
 , σ2eI
)
,
[βi|Xi = x,Gi = g] ∼ N2(β(g)x ,Γ),
and
[Gi|Xi = x] ∼Multinomial(pix),
where βTi =(βi0, βi1) is the random intercept and slope, Xi is the fixed effect variable, such
as an indicator for treatment group, pix is the vector of proportions of subjects with X = x
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within the subjects who fall in different missing patterns. Once pix and β
(g)
x are estimated,
the overall treatment effect can be combined as follows
E(β|Xi = x) =
M∑
g=1
pi(g)x β
(g)
x . (5.3)
5.3 PROPOSED METHOD
We use the same design described in Figure 6 in Chapter 4 and follow the same notation as
well. With the NMAR data, each subject has a set of observed data consist of the following
n independent vectors
{Vi, Xji, Li, Ri, RiZ1i, (1−Ri)Z ′1i, Gi, (tim, Yim),m = 1, 2, . . . ,M ; } , i = 1, 2, . . . , n,
where n is the total number of subjects in the sample; Vi is the baseline characteristics such
as age; Xi is the initial treatment indicator, Xji=1 when the i
th subject was randomized to
Aj, 0 otherwise; Li is the vector of covariates observed during the initial stage, Z1i and Z
′
1i
are the second-stage treatment indicators for B1 and B
′
1, respectively, i.e., Z1i=1 if the i
th
subject received B1, and Z1i=0 otherwise. Similarly, Z
′
1i=1 if the i
th subject received B′1,
0 otherwise; Gi is the dropout indicator, Gi = 1 for completers, Gi = 2 for the dropouts
before M th visit, and Gi = 3 for the dropouts before (M − 1)th visit and so forth; Yim is the
outcome observed at time tim for the subject i, m = 1, 2, . . . ,M . Let us define Z2i = 1−Z1i
and Z ′2i = 1 − Z ′1i so that Z2i and Z ′2i respectively represents the indicators for B2 and B′2
respectively. We assume a monotone missing pattern as illustrated in Figure 10.
As in Section 4.3, estimation of the treatment regime effects are conducted separately for
each treatment sequence. In addition, the data are stratified by the dropout pattern within
each observed sequence of treatments in order to model the NMAR component. The same
consistency assumption described in Section ?? is applied, and the goal is to estimate the
overall treatment regime effects by utilizing the observed data. We propose a method to
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Figure 10: Monotone Missing Patterns
estimate the treatment regime effects by incorporating a pattern-mixture model for missing
data. We refer to this as pattern-mixture model (PMM) method where the overall treatment
regime effects β(AjBkB
′
l) for j, k, l = 1, 2 are estimated in the following three steps.
Step 1: Estimation of treatment effects for dropout patterns per observed treat-
ment sequence. For g = 1, 2, ..M , we estimate the treatment effect per dropout pattern
β(g)(AjBk) for responders and β
(g)(AjB
′
l) for non-responders. Specifically, we fit M random-
coefficient models separately for the responder and non-responders each treatment sequence
as follows
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and,
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(g)
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V Ti α
(g)(AjB
′
l) + L
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i γ
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In addition, for g = 1, 2, ..M , the empirical dropout rate for observed treatment sequences
pˆi
(g)
AjBk
and pˆi
(g)
AjB′l
are estimated as follows,
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pˆi
(g)
AjBk
=
∑n
i=1XjiRiZkiI(Gi = g)∑n
i=1XjiRiZki
j, k = 1, 2.
and
pˆi
(g)
AjB′l
=
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i=1Xji(1−Ri)Z ′liI(Gi = g)∑n
i=1Xji(1−Ri)Z ′li
j, l = 1, 2.
Step 2: Estimation of treatment effects for observed treatment sequences. Drop-
out pattern-specific treatment effect estimates are then combined as follows to obtain the
treatment-sequence-specific estimates
βˆ(AjBk) =
M∑
g=1
pˆi
(g)
AjBk
βˆ(g)(AjBk) j, k = 1, 2.
and
βˆ(AjB
′
l) =
M∑
g=1
pˆi
(g)
AjB′l
βˆ(g)(AjB
′
l) j, l = 1, 2.
Variance of these estimates are obtained as follows
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The variance of βˆ(AjB
′
l) is estimated in a similar manner.
Step 3: Estimation of the overall treatment regime effects. Finally, the estimation
of the treatment effect per treatment regime are combined as follows
βˆ(AjBkB
′
l) = pˆirβˆ(AjBk) + (1− pˆir)βˆ(AjB′l) j, k, l = 1, 2.
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where the empirical response rate are estimated as
pˆir(Aj) =
∑n
i=1XjiRi∑n
i=1Xji
, j = 1, 2. (5.5)
The variance of βˆ(AjBkB
′
l) is estimated exactly the same way as the two-step method
described in Chapter 4.
5.4 SIMULATION STUDY
We conducted several simulation studies to examine the performance of the pattern-mixture
model in estimating regime effects in the presence of non-ignorable missing data. As de-
scribed in Chapter 4, we generated data to simulate a two-stage randomized study as shown
in Figure 6. The outcomes are generated from a multivariate normal distribution, and the
number of follow-up visits during the second stage is set to four to mimic the REVAMP
study. Again similar to the previous chapter, since the subjects who were randomized to A1
and A2 are independent, we only generated data for the subjects with A1 treatment, and
therefore, we will have only four treatment regimes, namely, A1B1B
′
1, A1B1B
′
2, A1B2B
′
1, and
A1B2B
′
2.
Following the definition of NMAR described in Section 5.2, in order to generate NMAR
data, we need to allow the distribution of missing data to depend on the missing outcome
itself. Therefore, we first create the following models to obtain the probability of missing Y3
and/or Y4
P (G = 1|age, Y4) = exp[φ1 ∗ age+ φ2 ∗ Y4]
1 + exp[φ1 ∗ age+ φ2 ∗ Y4] ,
and similarly, we fit a model for the missing Y3,
P (G = 2|age, Y3) = exp[φ1 ∗ age+ φ3 ∗ Y3]
1 + exp[φ1 ∗ age+ φ3 ∗ Y3] .
Based on the probabilities, the missing data indicator M1 and M2 are drawn from a Bernoulli
distribution with probability of success P (G = 1|age, Y4) and P (G = 2|age, Y3), respectively.
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Then the dropout indicator Gi is created: Gi = 1 if M1 = 0 and M2 = 0, Gi = 2 if M1 = 1
and M2 = 0, and Gi = 3 if M1 = 1 and M2 = 1. Approximately 40% and 60% of NMAR
data are generated by setting φ1 = -0.09, and φ2 = φ3 = 0.08 for 40% missing data, and φ1
= -0.08, φ2 = φ3 = 0.08 for 60% missing data.
Similar to the simulation studies in Chapter 4, we have tested the proposed method in
two different scenarios. In simulation scenario 1, we assumed that there were clear treat-
ment differences among four treatment sequences, while in simulation scenario 2, there was
no treatment differences. The specification of true parameters are exactly the same as in
Chapter 4; therefore, we set β(A1B1B
′
1) = -2.25, β(A1B1B
′
2) = -1.50, β(A1B2B
′
1) = -1.05,
and β(A1B2B
′
2) = -0.30. for scenario 1, and these four parameters are set to 0 for the second
scenario.
Table 12 shows the results of scenario 1 and 2 when the data are NMAR. The PMM
estimator is compared with the two-step estimator proposed in Chapter 4. One of the
assumptions for using the two-step method is that the missing data have to be at least
missing at random. Here we examine the performance of the method if the assumption
was violated. The simulation study showed that the bias for the PMM method is generally
smaller than the one for the two-step method. The relative bias for two-step method ranges
from 2% to s high as 17% whereas the same for PMM method ranges from 0.7% to 7%. The
coverage rate for the PMM method is generally higher compared to the Two-step method.
For the first scenario, the coverage rates for the PMM method range between 88.0% and
99.2%, while the rates for the two-step method range between 80.4% and 92.6%. For the
scenario 2, the difference is not very obvious because the treatment effects are set to 0. This
means that the effect of NMAR is smaller compared to the scenario 1. Overall, the PMM
estimator is approximately asymptotically unbiased, and showed an improvement over the
two-step method applied for the NMAR data.
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Table 12: Simulation result for two-step and PMM methods with 40% and 60%
NMAR data. Monte Carlo mean, Monte Carlo standard error, standard error, and
coverage rate (based on 95% C.I.) for all treatment regimes when the treatment regimes
differ and when there were no effects of treatment regime
Two-step Method PMM Method
MissingTreatment True MC Mean MC Coverage MC Mean MC Coverage
Rate Regime Param. (SE) SE Rate(%) (SE) SE Rate(%)
40% A1B1B
′
1 -2.25 -2.27(0.045) 0.045 92.6 -2.26(0.048) 0.061 98.0
A1B1B
′
2 -1.50 -1.53(0.056) 0.048 85.2 -1.15(0.059) 0.058 93.0
A1B2B
′
1 -1.05 -1.08(0.056) 0.048 85.2 -1.07(0.059) 0.067 96.8
A1B2B
′
2 -0.30 -0.34(0.051) 0.047 82.0 -0.32(0.054) 0.047 89.0
60% A1B1B
′
1 -2.25 -2.28(0.045) 0.046 92.6 -2.26(0.050) 0.065 99.2
A1B1B
′
2 -1.50 -1.53(0.055) 0.049 84.0 -1.51(0.062) 0.060 94.2
A1B2B
′
1 -1.05 -1.09(0.055) 0.049 83.4 -1.07(0.064) 0.070 95.4
A1B2B
′
2 -0.30 -0.35(0.048) 0.048 80.4 -0.32(0.056) 0.050 88.0
40% A1B1B
′
1 0.00 -0.04(0.047) 0.047 89.2 -0.01(0.054) 0.050 93.2
A1B1B
′
2 0.00 -0.04(0.047) 0.047 88.4 -0.01(0.055) 0.051 92.8
A1B2B
′
1 0.00 -0.04(0.046) 0.047 88.2 -0.01(0.055) 0.046 87.8
A1B2B
′
2 0.00 -0.04(0.047) 0.047 87.8 -0.01(0.056) 0.047 88.0
60% A1B1B
′
1 0.00 -0.05(0.048) 0.048 84.6 -0.02(0.058) 0.053 92.8
A1B1B
′
2 0.00 -0.05(0.049) 0.048 83.8 -0.02(0.059) 0.054 92.2
A1B2B
′
1 0.00 -0.05(0.048) 0.048 84.4 -0.02(0.060) 0.049 87.4
A1B2B
′
2 0.00 -0.05(0.049) 0.049 83.8 -0.02(0.060) 0.050 86.8
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5.5 CONCLUSION
In this chapter, we used pattern-mixture model (PMM) in conjunction with the two-step and
three-step methods described in earlier chapters to assess the effect of two-stage treatment
regimes on longitudinally observed outcome data when data are not missing at random but
monotone. The PMM method stratifies the data according observed treatment sequence by
the dropout pattern (monotonicity). Simulation studies were conducted to examine how the
PMM method performed in large sample properties, and also to compare the results to those
from the two-step method proposed in Chapter 4. The simulation result showed that the
PMM method provides improved estimates over the two-step method in terms of the relative
bias and the 95% coverage rate when there are monotone missing data and the missing data
mechanism depends on the missing outcome itself.
One limitation of this method is, similar to any stratified data analysis, the sample size
needs to be sufficiently large within each strata. When there are only a few subjects falls in
the stratified group, either the estimation of the parameter of interest may not be possible,
or might produce biased result.
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6.0 CONCLUSION
Adaptive treatment regimes are sets of rules that govern treatment assignment in a time-
varying course of treatment based on observed covariates and intermediate responses. Such
regimes are very common in biomedical studies of cancer, depression and AIDS since they
provide patient-specific overall plan for treatment. Statistical inference for treatment regimes
using a summary outcome measure such as time-to-event and mean response has been well-
studied in the literature. However, statistical methods for assessing the effect of treatment
strategies on repeated measures data are not well-developed. In this thesis, we worked on
two types of outcomes arising from a two-stage sequentially randomization design, namely,
survival and longitudinal data.
First, for the time-to-event data, we adapted an inverse-probability weighting approach
to generalize the standard Kaplan-Meier estimates in two-stage randomized setting. The
proposed method was compared with the two existing methods (i.e. the marginal mean
model based estimator and the weighted risk set estimator) using simulation studies. Our
simulation studies showed that the proposed weighted Kaplan-Meier method was asymptot-
ically unbiased, and performed very similar to the two existing methods. The advantage of
the proposed method is that it is quite simple to use, particularly the variance estimator
for this method is expressed explicitly in a much simplified form compared to the other
two estimators. Next, for the longitudinal data, we introduced three methods to assess the
effect of treatment regimes. We proposed two methods (i.e. two- and three-step methods),
which took two different approaches to estimate the treatment regime effects. The two-step
method adapted mixed model techniques to estimate the observed treatment sequence ef-
fects, and then combined those estimates to obtain the overall treatment regime effect by
taking their weighted averages. For the three-step method, a multiple imputation method
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was used to impute outcomes for those who were not consistent with the regime of interest.
Since everyone was consistent with every regime after the imputation process, the treatment
regime effect was directly estimated by fitting a mixed model for each treatment regime. The
simulation studies showed that both methods produce approximately unbiased results and
provide uniform coverage rates for 95% confidence intervals when the data are either com-
plete, missing completely at random, or missing at random. When the data are not missing
at random (NMAR) however, these methods may produce biased results. To overcome this
limitation, we applied pattern-mixture model approach ( PMM method) to assess the treat-
ment regime effects when the data are NMAR but monotone. The pattern-mixture model
approach was used in conjunction with the two-step method. First, the data were stratified
by the missing data pattern within each group of observed treatment sequence. Next, for
each stratified data, the parameter of interest was estimated, and the treatment sequence
effects were estimated by taking the weighted averages. Finally the overall treatment regime
effects were estimated by combining the estimated treatment sequence effects with the em-
pirical missing data response rate. The simulation studies were conducted to examine the
performance of the PMM method, and the results were compared to those obtained using
the two-step method (assuming that the data was complete). The results showed that the
PMM method had minimal bias, and showed a great improvement over the two-step method
in terms of bias and coverage probabilities.
Assessing the effect of treatment strategies on longitudinally observed outcome data is
important in identifying effective treatment strategies for treating chronic diseases such as
AIDS, depression and cancer. Proposed statistical methods provide useful tools for unbiased
estimation of the effects of treatment strategies from sequentially randomized (two-stage)
designs. Availability of these methods will help advance the research in AIDS, cancer,
depression, hepatitis and other disease areas.
73
BIBLIOGRAPHY
[1] R M. Stone, D T. Berg, S L. George, R K. Dodge, P A. Paciucci, P. Schulman, E J. Lee,
J O. Moore, B L. Powell, and C A. Schiffer. Granulocytemacrophage colony-stimulating
factor after initial chemotherapy for elderly patients with primary acute myelogenous
leukimia. The New England Journal of Medicine, 332:1671–1677, 1995.
[2] S A. Murphy, M J. Van Der Laan, and J M. Robins. Marginal mean models for dynamic
regimes. Journal of American Statistical Association, 96:1410–1423, 2001.
[3] S.A. Murphy. Optimal dynamic treatment regimes (with discussion). Journal of Royal
Statistical society, 65:331–336, 2003.
[4] J K. Lunceford, M. Davidian, and A A. Tsiatis. Estimation of survival distributions
of treatment policies in two-stage randomization designs in clinical trials. Biometrics,
58:48–57, 2002.
[5] A S. Wahed and A A. Tsiatis. Optimal estimator for the survival distribution and
related quantities for treatment policies in two-stage randomization designs in clinical
trials. Biometrics, 60(1):124–133, 2004.
[6] A S. Wahed and A A. Tsiatis. Semi-parametric efficient estimation of the survival
distribution for treatment policies in two-stage randomization designs in clinical trials
with censored data. Biometrika, 93:147–161, 2006.
[7] X. Guo and A A. Tsiatis. A weighted risk set estimator for survival distributions in
two-stage randomization designs with censored survival data. The International Journal
of Biostatistics, 1:00–00, 2005.
[8] M A. Hernan and J M. Robins. Estimating causal effects from epidemiological data. J
Epidemiol Community Health, 60(7):578–86, 2006.
[9] Y. Lokhnygina and J D. Helterbrand. Cox regression methods for two-stage random-
ization design. Biometrics, 63:422–428, 2007.
[10] P F. Thall, L H. Wooten, C J. Logothetis, and N M. Tannir R .Milikan. Baysesian and
frequentest two-stage treatment strategies based on sequential failure times subject to
interval centering. Statistics in Medicine, 26:4687–4702, 2007.
74
[11] E L. Kaplan and P. Meier. Nonparametric estimation from incomplete observations.
Journal of the American Statistical Association, 53:457–481, 1958.
[12] M. Greenwood. The natural duration of cancer. reports on public health and medical
subjects. London: Her Majesty’s Stationery Office, 33:1–26, 1926.
[13] O O. Aalen. Nonparametric inference for a family of counting processes. Annals of
Statistics, 6:701–726, 1978.
[14] N M. Laird and J H. Ware. Random effects models for longitudinal data. Biometrics,
38:963–974, 1982.
[15] N T. Longford. Random Coefficients Models. Oxford University Press, Oxford, 1993.
[16] H. Goldstein. Multilevel Statistical Models (third edition). Edward Arnold, London,
2003.
[17] H. Brown and R. Prescott. Applied Mixed Models in Medicine. John Wiley & Sons,
Inc., England, 2006.
[18] D B. Rubin. Inference and missing data (with discussion). Biometrika, 63:581–592,
1976.
[19] RJ A. Little and D B. Rubin. Statistical Analysis with Missing Data. John Wiley &
Sons, Inc., New Jersey, 2002.
[20] RJ A. Little. Modeling the drop-out mechanism in repeated-measures studies. Journal
of American Statistical Association, 90:1112–1121, 1995.
[21] J. Heckman. The common structure of statistical models of truncation, sample selection
and limited dependable variables, and a simple estimator for such models. Annals of
Economic and Social Mesurement, 5:475–492, 1976.
[22] PW. Lavori and R. Dawson. A design of for testing clinical strategies: biased individually
tailored within-subject randomization. Journal of the Royal Statistical society, 163:29–
38, 2000.
[23] J M. Robins, A. Rotnitzky, and L P. Zhao. Estimation of regression coefficients when
some regressors are not always observed. Journal of the American Statistical Association,
89:846–866, 1994.
[24] J. Xie and C. Liu. Adjusted kaplan-meier estimator and log-rank test with inverse
probability of treatment weighting for survival data. Statistics in Medicine, 24:3089–
3110, 2005.
[25] M H. Trivedi, J H. Kocsis, M E. Thase, D W. Morris, S R. Wisniewski, A C. Leon, A J.
Gelenberg, D N. Klein, G. Niederehe, A F. Schatzberg, P T. Ninan, and M B. Keller.
75
Revamp - research evaluating the value of augmenting medication with psychotherapy:
Rationale and design. Psychopharmacology Bulletin, 41:5–7, 2008.
[26] K Y. Liang and S L. Zeger. Longitudinal data analysis using generalized linear models.
Biometrika, 73:13–22, 1986.
[27] S L. Zeger and K Y. Liang. Longitudinal data analysis for discrete and continuous
outcomes. Biometrics, 42:121–130, 1986.
[28] P W. Holland. Statistics and causal inference. Journal of the American Statistical
Association, 81:945–960, 1986.
[29] H. Ko, J W. Hogan, and Mayer K H. Mayer. Estimating causal treatment effects from
longitudinal hiv natural history studies using marginal structural models. Biometrics,
59(1):152–62, 2003.
[30] J M. Robins. Causal Inference from complex longitudinal data. In Latent Variable Mod-
eling and Applications to Causality, M Berkane (ed). Springer-Verlag, New York, 1997.
[31] R C. Littell, G A. Milliken, W W. Stroup, and R D. Wolfinger. SAS System for Mixed
Models. SAS Institute., Cary, NC, 1996.
[32] J C. Pinheiro and D M. Bates. Mixed-Effect Models in S and S-plus. Springer-Verlag,
New York, 1994.
[33] G W. Oehlert. A note on the delta method. The American Statistician, 46:27–29, 1992.
76
